Slot System
Featured Buckets
Featured Buckets Admin
Reverse Chronological Sort
Allow Teaser Image

Scaly Plaque With Pustules and Anonychia on the Middle Finger

Article Type
Changed
Thu, 12/15/2022 - 14:59
Display Headline
Scaly Plaque With Pustules and Anonychia on the Middle Finger

The Diagnosis: Acrodermatitis Continua of Hallopeau

Acrodermatitis continua of Hallopeau (ACH) is considered to be a form of acropustular psoriasis that presents as a sterile, pustular eruption initially affecting the fingertips and/or toes.1 The slow-growing pustules typically progress locally and can lead to onychodystrophy and/or osteolysis of the underlying bone.2,3 Most commonly affecting adult women, ACH often begins following local trauma to or infection of a single digit.4 As the disease progresses proximally, the small pustules burst, leaving a shiny, erythematous surface on which new pustules can develop. These pustules have a tendency to amalgamate, leading to the characteristic clinical finding of lakes of pus. Pustules frequently appear on the nail matrix and nail bed presenting as severe onychodystrophy and ultimately anonychia.5,6 Rarely, ACH can be associated with generalized pustular psoriasis as well as conjunctivitis, balanitis, and fissuring or annulus migrans of the tongue.2,7

Diagnosis can be established based on clinical findings, biopsy, and bacterial and fungal cultures revealing sterile pustules.8,9 Histologic findings are similar to those seen in pustular psoriasis, demonstrating subcorneal neutrophilic pustules, Munro microabscesses, and dilated blood vessels with lymphocytic infiltrate in the papillary dermis.10

Due to the refractory nature of the disease, there are no recommended guidelines for treatment of ACH. Most successful treatment regimens consist of topical psoriasis medications combined with systemic psoriatic therapies such as cyclosporine, methotrexate, acitretin, or biologic therapy.8,11-16 Our patient achieved satisfactory clinical improvement with clobetasol propionate ointment 0.05% twice daily alternating with calcipotriene cream 0.005% twice daily.

References
  1. Suchanek J. Relation of Hallopeau’s acrodermatitis continua to psoriasis. Przegl Dermatol. 1951;1:165-181.
  2. Adam BA, Loh CL. Acropustulosis (acrodermatitis continua) with resorption of terminal phalanges. Med J Malaysia. 1972;27:30-32.
  3. Mrowietz U. Pustular eruptions of palms and soles. In: Wolff K, Goldsmith LS, Katz SI, et al, eds. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill; 2007:215-218.
  4. Yerushalmi J, Grunwald MH, Hallel-Halevy D, et al. Chronic pustular eruption of the thumbs. diagnosis: acrodermatitis continue of Hallopeau (ACH). Arch Dermatol. 2000:136:925-930.
  5. Granelli U. Impetigo herpetiformis; acrodermatitis continue of Hallopeau and pustular psoriasis; etiology and pathogenesis and differential diagnosis. Minerva Dermatol. 1956;31:120-126.
  6. Mobini N, Toussaint S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In: Elder DE, Elenitsas R, Johnson B, et al, eds. Lever’s Histopathology of the Skin. 9th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2005:174-210.
  7. Radcliff-Crocker H. Diseases of the Skin: Their Descriptions, Pathology, Diagnosis and Treatment. Philadelphia, PA: P. Blakiston, Son, & Co; 1888.
  8. Sehgal VN, Verma P, Sharma S, et al. Review: acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol. 2011;50:1195-1211.
  9. Post CF, Hopper ME. Dermatitis repens: a report of two cases with bacteriologic studies. AMA Arc Derm Syphilol. 1951;63:220-223.
  10. Sehgal VN, Sharma S. The significance of Gram’s stain smear, potassium hydroxide mount, culture and microscopic pathology in the diagnosis of acrodermatitis continua of Hallopeau. Skinmed. 2011;9:260-261.
  11. Mosser G, Pillekamp H, Peter RU. Suppurative acrodermatitis continua of Hallopeau. a differential diagnosis of paronychia. Dtsch Med Wochenschr. 1998;123:386-390.
  12. Piquero-Casals J, Fonseca de Mello AP, Dal Coleto C, et al. Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of Hallopeau. Cutis. 2002;70:106-108.
  13. Tsuji T, Nishimura M. Topically administered fluorouracil in acrodermatitis continua of Hallopeau. Arch Dermatol. 1991;127:27-28.
  14. Van de Kerkhof PCM. In vivo effects of vitamin D3 analogs. J Dermatolog Treat. 1998;(suppl 3):S25-S29.
  15. Kokelj F, Plozzer C, Trevisan G. Uselessness of topical calcipotriol as monotherapy for acrodermatitis continua of Hallopeau. Acta Derm Venereol. 2001;81:153.
  16. Schneider LA, Hinrichs R, Scharffetter-Kochanek K. Phototherapy and photochemotherapy. Clin Dermatol. 2008;26:464-476.
Article PDF
Author and Disclosure Information

Ms. Chandra is from the University of Missouri-Kansas City School of Medicine. Drs. Rajpara and Blackmon are from the Department of Dermatology, University of Kansas Medical Center, Kansas City.

The authors report no conflict of interest.

Correspondence: Anand Rajpara, MD, 3901 Rainbow Blvd, Kansas City, KS 66160 ([email protected]).

Issue
Cutis - 96(6)
Publications
Topics
Page Number
E1-E2
Legacy Keywords
acrodermatitis continua of hallopeau;generalized pustular psoriasis;systemic immunosuppression;phototherapy;psoriasis
Sections
Author and Disclosure Information

Ms. Chandra is from the University of Missouri-Kansas City School of Medicine. Drs. Rajpara and Blackmon are from the Department of Dermatology, University of Kansas Medical Center, Kansas City.

The authors report no conflict of interest.

Correspondence: Anand Rajpara, MD, 3901 Rainbow Blvd, Kansas City, KS 66160 ([email protected]).

Author and Disclosure Information

Ms. Chandra is from the University of Missouri-Kansas City School of Medicine. Drs. Rajpara and Blackmon are from the Department of Dermatology, University of Kansas Medical Center, Kansas City.

The authors report no conflict of interest.

Correspondence: Anand Rajpara, MD, 3901 Rainbow Blvd, Kansas City, KS 66160 ([email protected]).

Article PDF
Article PDF

The Diagnosis: Acrodermatitis Continua of Hallopeau

Acrodermatitis continua of Hallopeau (ACH) is considered to be a form of acropustular psoriasis that presents as a sterile, pustular eruption initially affecting the fingertips and/or toes.1 The slow-growing pustules typically progress locally and can lead to onychodystrophy and/or osteolysis of the underlying bone.2,3 Most commonly affecting adult women, ACH often begins following local trauma to or infection of a single digit.4 As the disease progresses proximally, the small pustules burst, leaving a shiny, erythematous surface on which new pustules can develop. These pustules have a tendency to amalgamate, leading to the characteristic clinical finding of lakes of pus. Pustules frequently appear on the nail matrix and nail bed presenting as severe onychodystrophy and ultimately anonychia.5,6 Rarely, ACH can be associated with generalized pustular psoriasis as well as conjunctivitis, balanitis, and fissuring or annulus migrans of the tongue.2,7

Diagnosis can be established based on clinical findings, biopsy, and bacterial and fungal cultures revealing sterile pustules.8,9 Histologic findings are similar to those seen in pustular psoriasis, demonstrating subcorneal neutrophilic pustules, Munro microabscesses, and dilated blood vessels with lymphocytic infiltrate in the papillary dermis.10

Due to the refractory nature of the disease, there are no recommended guidelines for treatment of ACH. Most successful treatment regimens consist of topical psoriasis medications combined with systemic psoriatic therapies such as cyclosporine, methotrexate, acitretin, or biologic therapy.8,11-16 Our patient achieved satisfactory clinical improvement with clobetasol propionate ointment 0.05% twice daily alternating with calcipotriene cream 0.005% twice daily.

The Diagnosis: Acrodermatitis Continua of Hallopeau

Acrodermatitis continua of Hallopeau (ACH) is considered to be a form of acropustular psoriasis that presents as a sterile, pustular eruption initially affecting the fingertips and/or toes.1 The slow-growing pustules typically progress locally and can lead to onychodystrophy and/or osteolysis of the underlying bone.2,3 Most commonly affecting adult women, ACH often begins following local trauma to or infection of a single digit.4 As the disease progresses proximally, the small pustules burst, leaving a shiny, erythematous surface on which new pustules can develop. These pustules have a tendency to amalgamate, leading to the characteristic clinical finding of lakes of pus. Pustules frequently appear on the nail matrix and nail bed presenting as severe onychodystrophy and ultimately anonychia.5,6 Rarely, ACH can be associated with generalized pustular psoriasis as well as conjunctivitis, balanitis, and fissuring or annulus migrans of the tongue.2,7

Diagnosis can be established based on clinical findings, biopsy, and bacterial and fungal cultures revealing sterile pustules.8,9 Histologic findings are similar to those seen in pustular psoriasis, demonstrating subcorneal neutrophilic pustules, Munro microabscesses, and dilated blood vessels with lymphocytic infiltrate in the papillary dermis.10

Due to the refractory nature of the disease, there are no recommended guidelines for treatment of ACH. Most successful treatment regimens consist of topical psoriasis medications combined with systemic psoriatic therapies such as cyclosporine, methotrexate, acitretin, or biologic therapy.8,11-16 Our patient achieved satisfactory clinical improvement with clobetasol propionate ointment 0.05% twice daily alternating with calcipotriene cream 0.005% twice daily.

References
  1. Suchanek J. Relation of Hallopeau’s acrodermatitis continua to psoriasis. Przegl Dermatol. 1951;1:165-181.
  2. Adam BA, Loh CL. Acropustulosis (acrodermatitis continua) with resorption of terminal phalanges. Med J Malaysia. 1972;27:30-32.
  3. Mrowietz U. Pustular eruptions of palms and soles. In: Wolff K, Goldsmith LS, Katz SI, et al, eds. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill; 2007:215-218.
  4. Yerushalmi J, Grunwald MH, Hallel-Halevy D, et al. Chronic pustular eruption of the thumbs. diagnosis: acrodermatitis continue of Hallopeau (ACH). Arch Dermatol. 2000:136:925-930.
  5. Granelli U. Impetigo herpetiformis; acrodermatitis continue of Hallopeau and pustular psoriasis; etiology and pathogenesis and differential diagnosis. Minerva Dermatol. 1956;31:120-126.
  6. Mobini N, Toussaint S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In: Elder DE, Elenitsas R, Johnson B, et al, eds. Lever’s Histopathology of the Skin. 9th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2005:174-210.
  7. Radcliff-Crocker H. Diseases of the Skin: Their Descriptions, Pathology, Diagnosis and Treatment. Philadelphia, PA: P. Blakiston, Son, & Co; 1888.
  8. Sehgal VN, Verma P, Sharma S, et al. Review: acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol. 2011;50:1195-1211.
  9. Post CF, Hopper ME. Dermatitis repens: a report of two cases with bacteriologic studies. AMA Arc Derm Syphilol. 1951;63:220-223.
  10. Sehgal VN, Sharma S. The significance of Gram’s stain smear, potassium hydroxide mount, culture and microscopic pathology in the diagnosis of acrodermatitis continua of Hallopeau. Skinmed. 2011;9:260-261.
  11. Mosser G, Pillekamp H, Peter RU. Suppurative acrodermatitis continua of Hallopeau. a differential diagnosis of paronychia. Dtsch Med Wochenschr. 1998;123:386-390.
  12. Piquero-Casals J, Fonseca de Mello AP, Dal Coleto C, et al. Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of Hallopeau. Cutis. 2002;70:106-108.
  13. Tsuji T, Nishimura M. Topically administered fluorouracil in acrodermatitis continua of Hallopeau. Arch Dermatol. 1991;127:27-28.
  14. Van de Kerkhof PCM. In vivo effects of vitamin D3 analogs. J Dermatolog Treat. 1998;(suppl 3):S25-S29.
  15. Kokelj F, Plozzer C, Trevisan G. Uselessness of topical calcipotriol as monotherapy for acrodermatitis continua of Hallopeau. Acta Derm Venereol. 2001;81:153.
  16. Schneider LA, Hinrichs R, Scharffetter-Kochanek K. Phototherapy and photochemotherapy. Clin Dermatol. 2008;26:464-476.
References
  1. Suchanek J. Relation of Hallopeau’s acrodermatitis continua to psoriasis. Przegl Dermatol. 1951;1:165-181.
  2. Adam BA, Loh CL. Acropustulosis (acrodermatitis continua) with resorption of terminal phalanges. Med J Malaysia. 1972;27:30-32.
  3. Mrowietz U. Pustular eruptions of palms and soles. In: Wolff K, Goldsmith LS, Katz SI, et al, eds. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill; 2007:215-218.
  4. Yerushalmi J, Grunwald MH, Hallel-Halevy D, et al. Chronic pustular eruption of the thumbs. diagnosis: acrodermatitis continue of Hallopeau (ACH). Arch Dermatol. 2000:136:925-930.
  5. Granelli U. Impetigo herpetiformis; acrodermatitis continue of Hallopeau and pustular psoriasis; etiology and pathogenesis and differential diagnosis. Minerva Dermatol. 1956;31:120-126.
  6. Mobini N, Toussaint S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In: Elder DE, Elenitsas R, Johnson B, et al, eds. Lever’s Histopathology of the Skin. 9th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2005:174-210.
  7. Radcliff-Crocker H. Diseases of the Skin: Their Descriptions, Pathology, Diagnosis and Treatment. Philadelphia, PA: P. Blakiston, Son, & Co; 1888.
  8. Sehgal VN, Verma P, Sharma S, et al. Review: acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol. 2011;50:1195-1211.
  9. Post CF, Hopper ME. Dermatitis repens: a report of two cases with bacteriologic studies. AMA Arc Derm Syphilol. 1951;63:220-223.
  10. Sehgal VN, Sharma S. The significance of Gram’s stain smear, potassium hydroxide mount, culture and microscopic pathology in the diagnosis of acrodermatitis continua of Hallopeau. Skinmed. 2011;9:260-261.
  11. Mosser G, Pillekamp H, Peter RU. Suppurative acrodermatitis continua of Hallopeau. a differential diagnosis of paronychia. Dtsch Med Wochenschr. 1998;123:386-390.
  12. Piquero-Casals J, Fonseca de Mello AP, Dal Coleto C, et al. Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of Hallopeau. Cutis. 2002;70:106-108.
  13. Tsuji T, Nishimura M. Topically administered fluorouracil in acrodermatitis continua of Hallopeau. Arch Dermatol. 1991;127:27-28.
  14. Van de Kerkhof PCM. In vivo effects of vitamin D3 analogs. J Dermatolog Treat. 1998;(suppl 3):S25-S29.
  15. Kokelj F, Plozzer C, Trevisan G. Uselessness of topical calcipotriol as monotherapy for acrodermatitis continua of Hallopeau. Acta Derm Venereol. 2001;81:153.
  16. Schneider LA, Hinrichs R, Scharffetter-Kochanek K. Phototherapy and photochemotherapy. Clin Dermatol. 2008;26:464-476.
Issue
Cutis - 96(6)
Issue
Cutis - 96(6)
Page Number
E1-E2
Page Number
E1-E2
Publications
Publications
Topics
Article Type
Display Headline
Scaly Plaque With Pustules and Anonychia on the Middle Finger
Display Headline
Scaly Plaque With Pustules and Anonychia on the Middle Finger
Legacy Keywords
acrodermatitis continua of hallopeau;generalized pustular psoriasis;systemic immunosuppression;phototherapy;psoriasis
Legacy Keywords
acrodermatitis continua of hallopeau;generalized pustular psoriasis;systemic immunosuppression;phototherapy;psoriasis
Sections
Questionnaire Body

A 69-year-old man presented to our dermatology clinic with a persistent rash on the right middle finger of 5 years’ duration (left). Physical examination revealed a well-demarcated scaly plaque with pustules and anonychia localized to the right middle finger (right). Fungal and bacterial cultures revealed sterile pustules. The patient was successfully treated with an occluded superpotent topical steroid alternating with a topical vitamin D analogue.

 

 

Disallow All Ads
Article PDF Media

What Is Your Diagnosis? Tinea Corporis

Article Type
Changed
Thu, 01/10/2019 - 13:26
Display Headline
What Is Your Diagnosis? Tinea Corporis

The Diagnosis: Tinea Corporis

Although contact dermatitis from the metal on the back of the watch was suspected, many modern wrist watches are made with stainless steel rather than nickel, which is a common contact allergen; therefore, other diagnoses were considered in the differential including irritant contact dermatitis, psoriasis, and tinea infection. A potassium hydroxide (KOH) preparation was performed to rule out tinea infection. Unexpectedly, the KOH preparation was positive for fungal hyphae, confirming a diagnosis of tinea corporis. The patient was treated with clotrimazole cream 1% twice daily for 3 weeks during which time the rash completely resolved.

 

Tinea corporis infection on the wrist of an 81-year-old woman. The lesion showed clinical characteristics that were suggestive of a dermatophyte infection but was somewhat atypical in appearance, as it lacked central clearing.

We present this case to stress the importance of performing KOH preparations even when the likelihood of tinea infection seems remote. At our institution, we teach our residents, “If it’s scaly, scrape it.” This adage has served us well. Tinea corporis may be mistaken for many other skin diseases, including eczema, psoriasis, and seborrheic dermatitis.1 A KOH preparation often is a helpful tool in confirming the diagnosis and should be performed when a dermatophyte infection is suspected. The KOH preparation is the most sensitive diagnostic test used to confirm dermatophyte infection, with 90% of infections showing positive results.2,3

Tinea infections may occur anywhere on the body, but areas that are prone to excessive heat and/or moisture are particularly susceptible.4 Dermatophyte infections typically present as annular, scaly, pruritic patches or plaques often with central clearing and an active border.1 In our patient, the lesion showed characteristics that were suggestive of a dermatophyte infection but was somewhat atypical in appearance, as it lacked central clearing (Figure). The 3 genera of dermatophytes—Trichophyton, Microsporum, and Epidermophyton—are common causes of fungal infections.2 The pathogenesis of dermatophytosis is the synthesis of keratinases that digest keratin and sustain the presence of the fungi. Local factors such as sweating and occlusion facilitate the activity of these organisms.2 In our case, the pathogenesis was believed to be due to the entrapment of moisture behind the patient’s watch, creating a favorable environment for fungal growth.

References
  1. Ely JW, Rosenfeld S, Seabury SM. Diagnosis and management of tinea infections. Am Fam Physician. 2014:90:702-710.
  2. Wolff K, Saavedra AP, Fitzpatrick TB. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. 7th ed. New York, NY: McGraw-Hill Medical; 2013.
  3. Levitt JO, Levitt BH, Akhavan A, et al. The sensitivity and specificity of potassium hydroxide smear and fungal culture relative to clinical assessment in the evaluation of tinea pedis: a pooled analysis (published online ahead of print June 22, 2010). Dermatol Res Pract. doi:10.1155/2010/764843.
  4. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra and piedra. Dermatol Clin. 2003;21:395-400.
Article PDF
Author and Disclosure Information

Ms. Gyurjyan is from the University of Virginia School of Medicine, Charlottesville. Dr. Wilson is from the Department of Dermatology, University of Virginia Health System, Charlottesville.

The authors report no conflict of interest.

Correspondence: Barbara Wilson, MD, Department of Dermatology, University of Virginia Health System, PO Box 800718, Charlottesville, VA 22908-0718 ([email protected]).

Issue
Cutis - 96(5)
Publications
Topics
Page Number
297, 326
Legacy Keywords
tinea corporis, fungal infection, KOH, potassium hydroxide, clotrimazole
Sections
Author and Disclosure Information

Ms. Gyurjyan is from the University of Virginia School of Medicine, Charlottesville. Dr. Wilson is from the Department of Dermatology, University of Virginia Health System, Charlottesville.

The authors report no conflict of interest.

Correspondence: Barbara Wilson, MD, Department of Dermatology, University of Virginia Health System, PO Box 800718, Charlottesville, VA 22908-0718 ([email protected]).

Author and Disclosure Information

Ms. Gyurjyan is from the University of Virginia School of Medicine, Charlottesville. Dr. Wilson is from the Department of Dermatology, University of Virginia Health System, Charlottesville.

The authors report no conflict of interest.

Correspondence: Barbara Wilson, MD, Department of Dermatology, University of Virginia Health System, PO Box 800718, Charlottesville, VA 22908-0718 ([email protected]).

Article PDF
Article PDF
Related Articles

The Diagnosis: Tinea Corporis

Although contact dermatitis from the metal on the back of the watch was suspected, many modern wrist watches are made with stainless steel rather than nickel, which is a common contact allergen; therefore, other diagnoses were considered in the differential including irritant contact dermatitis, psoriasis, and tinea infection. A potassium hydroxide (KOH) preparation was performed to rule out tinea infection. Unexpectedly, the KOH preparation was positive for fungal hyphae, confirming a diagnosis of tinea corporis. The patient was treated with clotrimazole cream 1% twice daily for 3 weeks during which time the rash completely resolved.

 

Tinea corporis infection on the wrist of an 81-year-old woman. The lesion showed clinical characteristics that were suggestive of a dermatophyte infection but was somewhat atypical in appearance, as it lacked central clearing.

We present this case to stress the importance of performing KOH preparations even when the likelihood of tinea infection seems remote. At our institution, we teach our residents, “If it’s scaly, scrape it.” This adage has served us well. Tinea corporis may be mistaken for many other skin diseases, including eczema, psoriasis, and seborrheic dermatitis.1 A KOH preparation often is a helpful tool in confirming the diagnosis and should be performed when a dermatophyte infection is suspected. The KOH preparation is the most sensitive diagnostic test used to confirm dermatophyte infection, with 90% of infections showing positive results.2,3

Tinea infections may occur anywhere on the body, but areas that are prone to excessive heat and/or moisture are particularly susceptible.4 Dermatophyte infections typically present as annular, scaly, pruritic patches or plaques often with central clearing and an active border.1 In our patient, the lesion showed characteristics that were suggestive of a dermatophyte infection but was somewhat atypical in appearance, as it lacked central clearing (Figure). The 3 genera of dermatophytes—Trichophyton, Microsporum, and Epidermophyton—are common causes of fungal infections.2 The pathogenesis of dermatophytosis is the synthesis of keratinases that digest keratin and sustain the presence of the fungi. Local factors such as sweating and occlusion facilitate the activity of these organisms.2 In our case, the pathogenesis was believed to be due to the entrapment of moisture behind the patient’s watch, creating a favorable environment for fungal growth.

The Diagnosis: Tinea Corporis

Although contact dermatitis from the metal on the back of the watch was suspected, many modern wrist watches are made with stainless steel rather than nickel, which is a common contact allergen; therefore, other diagnoses were considered in the differential including irritant contact dermatitis, psoriasis, and tinea infection. A potassium hydroxide (KOH) preparation was performed to rule out tinea infection. Unexpectedly, the KOH preparation was positive for fungal hyphae, confirming a diagnosis of tinea corporis. The patient was treated with clotrimazole cream 1% twice daily for 3 weeks during which time the rash completely resolved.

 

Tinea corporis infection on the wrist of an 81-year-old woman. The lesion showed clinical characteristics that were suggestive of a dermatophyte infection but was somewhat atypical in appearance, as it lacked central clearing.

We present this case to stress the importance of performing KOH preparations even when the likelihood of tinea infection seems remote. At our institution, we teach our residents, “If it’s scaly, scrape it.” This adage has served us well. Tinea corporis may be mistaken for many other skin diseases, including eczema, psoriasis, and seborrheic dermatitis.1 A KOH preparation often is a helpful tool in confirming the diagnosis and should be performed when a dermatophyte infection is suspected. The KOH preparation is the most sensitive diagnostic test used to confirm dermatophyte infection, with 90% of infections showing positive results.2,3

Tinea infections may occur anywhere on the body, but areas that are prone to excessive heat and/or moisture are particularly susceptible.4 Dermatophyte infections typically present as annular, scaly, pruritic patches or plaques often with central clearing and an active border.1 In our patient, the lesion showed characteristics that were suggestive of a dermatophyte infection but was somewhat atypical in appearance, as it lacked central clearing (Figure). The 3 genera of dermatophytes—Trichophyton, Microsporum, and Epidermophyton—are common causes of fungal infections.2 The pathogenesis of dermatophytosis is the synthesis of keratinases that digest keratin and sustain the presence of the fungi. Local factors such as sweating and occlusion facilitate the activity of these organisms.2 In our case, the pathogenesis was believed to be due to the entrapment of moisture behind the patient’s watch, creating a favorable environment for fungal growth.

References
  1. Ely JW, Rosenfeld S, Seabury SM. Diagnosis and management of tinea infections. Am Fam Physician. 2014:90:702-710.
  2. Wolff K, Saavedra AP, Fitzpatrick TB. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. 7th ed. New York, NY: McGraw-Hill Medical; 2013.
  3. Levitt JO, Levitt BH, Akhavan A, et al. The sensitivity and specificity of potassium hydroxide smear and fungal culture relative to clinical assessment in the evaluation of tinea pedis: a pooled analysis (published online ahead of print June 22, 2010). Dermatol Res Pract. doi:10.1155/2010/764843.
  4. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra and piedra. Dermatol Clin. 2003;21:395-400.
References
  1. Ely JW, Rosenfeld S, Seabury SM. Diagnosis and management of tinea infections. Am Fam Physician. 2014:90:702-710.
  2. Wolff K, Saavedra AP, Fitzpatrick TB. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology. 7th ed. New York, NY: McGraw-Hill Medical; 2013.
  3. Levitt JO, Levitt BH, Akhavan A, et al. The sensitivity and specificity of potassium hydroxide smear and fungal culture relative to clinical assessment in the evaluation of tinea pedis: a pooled analysis (published online ahead of print June 22, 2010). Dermatol Res Pract. doi:10.1155/2010/764843.
  4. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra and piedra. Dermatol Clin. 2003;21:395-400.
Issue
Cutis - 96(5)
Issue
Cutis - 96(5)
Page Number
297, 326
Page Number
297, 326
Publications
Publications
Topics
Article Type
Display Headline
What Is Your Diagnosis? Tinea Corporis
Display Headline
What Is Your Diagnosis? Tinea Corporis
Legacy Keywords
tinea corporis, fungal infection, KOH, potassium hydroxide, clotrimazole
Legacy Keywords
tinea corporis, fungal infection, KOH, potassium hydroxide, clotrimazole
Sections
Questionnaire Body

An 81-year-old woman presented with a 2-cm erythematous, scaly, pruritic rash on the left dorsal wrist localized to the skin under her watch. The patient first noticed the lesion 2 months prior. She moved the watch to the right wrist a few days prior to presentation and no symptoms developed in that location. No other areas of the skin were affected. She had no known allergies and was otherwise in good health.

Disallow All Ads
Alternative CME
Article PDF Media

Linear Bluish Black Papules on the Shoulder

Article Type
Changed
Thu, 01/10/2019 - 13:26
Display Headline
Linear Bluish Black Papules on the Shoulder

The Diagnosis: Agminated Blue Nevus

Agminated blue nevus is a rare melanocytic nevus that characteristically presents as a group of multiple small, bluish papules occurring in a well-circumscribed area.1 It also has been referred to as a plaque-type nevus2,3 and an eruptive blue nevus.4 Originally described by Upshaw et al2 in 1947, agminated blue nevi may be congenital or arise in early childhood and almost always occur on the trunk. The skin between the papules often is unaffected or sometimes may show bluish or brown pigmentation.4 Agminated blue nevi usually are smaller than 10 cm in diameter; however, rare cases have measured up to 24 cm.1,4-6 The incidence of agminated blue nevi is 2 times higher in males than in females.1

 



A biopsy of the lesion revealed pigmented dendritic melanocytes admixed with melanophages, forming fascicles and bundles (A)(H&E, original magnification ×10). In some areas the dermis was uninvolved. Higher magnification showed dendritic and epithelioid melanocytes extending down along the adnexal structures (B)(H&E, original magnification ×40).

Histopathologically, agminated blue nevi typically demonstrate the features of common and/or cellular blue nevi. Cytologic atypia and mitoses are rare.1 The degree of cellularity and pigmentation of the lesions is variable, and the presence of subcutaneous cellular nodules also has been described.5

In our patient, histologic evaluation revealed foci of diffuse dermal spindle cell proliferation composed of heavily pigmented dendritic melanocytes admixed with melanophages in a fibrotic stroma (Figure, A). The dermis was uninvolved in some areas and the melanocytes were epithelioid and formed fascicles and bundles that extended down adnexal structures in other areas (Figure, B). Junctional involvement of melanocytes, cellular atypia, and mitoses were not identified. Our case demonstrated a combination of histologic findings of a cellular blue nevus as well as features reminiscent of a deep penetrating nevus. The differential diagnosis of agminated blue nevus includes agminated Spitz nevus arising in a speckled lentiginous nevus,7 dermal melanocytosis, melanoma, and pilar neurocristic hamartoma. Pilar neurocristic hamartomas may resemble plaque-type blue nevi; however, the former show a predilection for the scalp, histologically demonstrate features that overlap with blue nevi and congenital nevi, and are associated with neural structures that show Schwannian differentiation.8 Agminated blue nevi usually are characterized by a benign clinical course, but few cases describing malignant changes with development of malignant melanoma have been reported.9,10 Therefore, recognition of the clinical and histopathologic spectrum of agminated blue nevus is critical in order to avoid diagnostic pitfalls and confusion with melanoma.

References
  1. Vélez A, del-Río E, Martín-de-Hijas C, et al. Agminated blue nevi: case report and review of the literature. Dermatology. 1993;186:144-148.
  2. Upshaw BY, Ghormley RK, Montgomery H. Extensive blue nevus of Jadassohn-Tièche; report of a case. Surgery. 1947;22:761-765.
  3. Pittman JL, Fisher BK. Plaque-type blue nevus. Arch Dermatol. 1976;112:1127-1128.
  4. Hendricks WM. Eruptive blue nevi. J Am Acad Dermatol.1981;4:50-53.
  5. Busam KJ, Woodruff JM, Erlandson RA, et al. Large plaque-type blue nevus with subcutaneous cellular nodules. Am J Surg Pathol. 2000;24:92-99.
  6. Shenfield HT, Maize JC. Multiple and agminated blue nevi. J Dermatol Surg Oncol. 1980;6:725-728.
  7. Misago N, Narisawa Y, Kohda H. A combination of speckled lentiginous nevus with patch-type blue nevus. J Dermatol. 1993;20:643-647.
  8. Bevona C, Tannous Z, Tsao H. Dermal melanocytic proliferation with features of a plaque-type blue nevus and neurocristic hamartoma. J Am Acad Dermatol. 2003;49:924-929.
  9. Yeh I, Fang Y, Busam KJ. Melanoma arising in a large plaque-type blue nevus with subcutaneous cellular nodules. Am J Surg Pathol. 2012;36:1258-1263.
  10. Zattra E, Salmaso R, Montesco MC, et al. Large plaque type blue nevus with subcutaneous cellular nodules. Eur J Dermatol. 2009;19:287-288.
Article PDF
Author and Disclosure Information

From the Department of Dermatology and Dermatopathology, University of Connecticut Health Center, Farmington.

The authors report no conflict of interest.

Correspondence: Katalin Ferenczi, MD, University of Connecticut Health Center, Department of Dermatology and Dermatopathology, 21 South Rd, Farmington, CT 06030 ([email protected]).

Issue
Cutis - 96(5)
Publications
Page Number
E10-E12
Legacy Keywords
blue nevus, agminated
Sections
Author and Disclosure Information

From the Department of Dermatology and Dermatopathology, University of Connecticut Health Center, Farmington.

The authors report no conflict of interest.

Correspondence: Katalin Ferenczi, MD, University of Connecticut Health Center, Department of Dermatology and Dermatopathology, 21 South Rd, Farmington, CT 06030 ([email protected]).

Author and Disclosure Information

From the Department of Dermatology and Dermatopathology, University of Connecticut Health Center, Farmington.

The authors report no conflict of interest.

Correspondence: Katalin Ferenczi, MD, University of Connecticut Health Center, Department of Dermatology and Dermatopathology, 21 South Rd, Farmington, CT 06030 ([email protected]).

Article PDF
Article PDF

The Diagnosis: Agminated Blue Nevus

Agminated blue nevus is a rare melanocytic nevus that characteristically presents as a group of multiple small, bluish papules occurring in a well-circumscribed area.1 It also has been referred to as a plaque-type nevus2,3 and an eruptive blue nevus.4 Originally described by Upshaw et al2 in 1947, agminated blue nevi may be congenital or arise in early childhood and almost always occur on the trunk. The skin between the papules often is unaffected or sometimes may show bluish or brown pigmentation.4 Agminated blue nevi usually are smaller than 10 cm in diameter; however, rare cases have measured up to 24 cm.1,4-6 The incidence of agminated blue nevi is 2 times higher in males than in females.1

 



A biopsy of the lesion revealed pigmented dendritic melanocytes admixed with melanophages, forming fascicles and bundles (A)(H&E, original magnification ×10). In some areas the dermis was uninvolved. Higher magnification showed dendritic and epithelioid melanocytes extending down along the adnexal structures (B)(H&E, original magnification ×40).

Histopathologically, agminated blue nevi typically demonstrate the features of common and/or cellular blue nevi. Cytologic atypia and mitoses are rare.1 The degree of cellularity and pigmentation of the lesions is variable, and the presence of subcutaneous cellular nodules also has been described.5

In our patient, histologic evaluation revealed foci of diffuse dermal spindle cell proliferation composed of heavily pigmented dendritic melanocytes admixed with melanophages in a fibrotic stroma (Figure, A). The dermis was uninvolved in some areas and the melanocytes were epithelioid and formed fascicles and bundles that extended down adnexal structures in other areas (Figure, B). Junctional involvement of melanocytes, cellular atypia, and mitoses were not identified. Our case demonstrated a combination of histologic findings of a cellular blue nevus as well as features reminiscent of a deep penetrating nevus. The differential diagnosis of agminated blue nevus includes agminated Spitz nevus arising in a speckled lentiginous nevus,7 dermal melanocytosis, melanoma, and pilar neurocristic hamartoma. Pilar neurocristic hamartomas may resemble plaque-type blue nevi; however, the former show a predilection for the scalp, histologically demonstrate features that overlap with blue nevi and congenital nevi, and are associated with neural structures that show Schwannian differentiation.8 Agminated blue nevi usually are characterized by a benign clinical course, but few cases describing malignant changes with development of malignant melanoma have been reported.9,10 Therefore, recognition of the clinical and histopathologic spectrum of agminated blue nevus is critical in order to avoid diagnostic pitfalls and confusion with melanoma.

The Diagnosis: Agminated Blue Nevus

Agminated blue nevus is a rare melanocytic nevus that characteristically presents as a group of multiple small, bluish papules occurring in a well-circumscribed area.1 It also has been referred to as a plaque-type nevus2,3 and an eruptive blue nevus.4 Originally described by Upshaw et al2 in 1947, agminated blue nevi may be congenital or arise in early childhood and almost always occur on the trunk. The skin between the papules often is unaffected or sometimes may show bluish or brown pigmentation.4 Agminated blue nevi usually are smaller than 10 cm in diameter; however, rare cases have measured up to 24 cm.1,4-6 The incidence of agminated blue nevi is 2 times higher in males than in females.1

 



A biopsy of the lesion revealed pigmented dendritic melanocytes admixed with melanophages, forming fascicles and bundles (A)(H&E, original magnification ×10). In some areas the dermis was uninvolved. Higher magnification showed dendritic and epithelioid melanocytes extending down along the adnexal structures (B)(H&E, original magnification ×40).

Histopathologically, agminated blue nevi typically demonstrate the features of common and/or cellular blue nevi. Cytologic atypia and mitoses are rare.1 The degree of cellularity and pigmentation of the lesions is variable, and the presence of subcutaneous cellular nodules also has been described.5

In our patient, histologic evaluation revealed foci of diffuse dermal spindle cell proliferation composed of heavily pigmented dendritic melanocytes admixed with melanophages in a fibrotic stroma (Figure, A). The dermis was uninvolved in some areas and the melanocytes were epithelioid and formed fascicles and bundles that extended down adnexal structures in other areas (Figure, B). Junctional involvement of melanocytes, cellular atypia, and mitoses were not identified. Our case demonstrated a combination of histologic findings of a cellular blue nevus as well as features reminiscent of a deep penetrating nevus. The differential diagnosis of agminated blue nevus includes agminated Spitz nevus arising in a speckled lentiginous nevus,7 dermal melanocytosis, melanoma, and pilar neurocristic hamartoma. Pilar neurocristic hamartomas may resemble plaque-type blue nevi; however, the former show a predilection for the scalp, histologically demonstrate features that overlap with blue nevi and congenital nevi, and are associated with neural structures that show Schwannian differentiation.8 Agminated blue nevi usually are characterized by a benign clinical course, but few cases describing malignant changes with development of malignant melanoma have been reported.9,10 Therefore, recognition of the clinical and histopathologic spectrum of agminated blue nevus is critical in order to avoid diagnostic pitfalls and confusion with melanoma.

References
  1. Vélez A, del-Río E, Martín-de-Hijas C, et al. Agminated blue nevi: case report and review of the literature. Dermatology. 1993;186:144-148.
  2. Upshaw BY, Ghormley RK, Montgomery H. Extensive blue nevus of Jadassohn-Tièche; report of a case. Surgery. 1947;22:761-765.
  3. Pittman JL, Fisher BK. Plaque-type blue nevus. Arch Dermatol. 1976;112:1127-1128.
  4. Hendricks WM. Eruptive blue nevi. J Am Acad Dermatol.1981;4:50-53.
  5. Busam KJ, Woodruff JM, Erlandson RA, et al. Large plaque-type blue nevus with subcutaneous cellular nodules. Am J Surg Pathol. 2000;24:92-99.
  6. Shenfield HT, Maize JC. Multiple and agminated blue nevi. J Dermatol Surg Oncol. 1980;6:725-728.
  7. Misago N, Narisawa Y, Kohda H. A combination of speckled lentiginous nevus with patch-type blue nevus. J Dermatol. 1993;20:643-647.
  8. Bevona C, Tannous Z, Tsao H. Dermal melanocytic proliferation with features of a plaque-type blue nevus and neurocristic hamartoma. J Am Acad Dermatol. 2003;49:924-929.
  9. Yeh I, Fang Y, Busam KJ. Melanoma arising in a large plaque-type blue nevus with subcutaneous cellular nodules. Am J Surg Pathol. 2012;36:1258-1263.
  10. Zattra E, Salmaso R, Montesco MC, et al. Large plaque type blue nevus with subcutaneous cellular nodules. Eur J Dermatol. 2009;19:287-288.
References
  1. Vélez A, del-Río E, Martín-de-Hijas C, et al. Agminated blue nevi: case report and review of the literature. Dermatology. 1993;186:144-148.
  2. Upshaw BY, Ghormley RK, Montgomery H. Extensive blue nevus of Jadassohn-Tièche; report of a case. Surgery. 1947;22:761-765.
  3. Pittman JL, Fisher BK. Plaque-type blue nevus. Arch Dermatol. 1976;112:1127-1128.
  4. Hendricks WM. Eruptive blue nevi. J Am Acad Dermatol.1981;4:50-53.
  5. Busam KJ, Woodruff JM, Erlandson RA, et al. Large plaque-type blue nevus with subcutaneous cellular nodules. Am J Surg Pathol. 2000;24:92-99.
  6. Shenfield HT, Maize JC. Multiple and agminated blue nevi. J Dermatol Surg Oncol. 1980;6:725-728.
  7. Misago N, Narisawa Y, Kohda H. A combination of speckled lentiginous nevus with patch-type blue nevus. J Dermatol. 1993;20:643-647.
  8. Bevona C, Tannous Z, Tsao H. Dermal melanocytic proliferation with features of a plaque-type blue nevus and neurocristic hamartoma. J Am Acad Dermatol. 2003;49:924-929.
  9. Yeh I, Fang Y, Busam KJ. Melanoma arising in a large plaque-type blue nevus with subcutaneous cellular nodules. Am J Surg Pathol. 2012;36:1258-1263.
  10. Zattra E, Salmaso R, Montesco MC, et al. Large plaque type blue nevus with subcutaneous cellular nodules. Eur J Dermatol. 2009;19:287-288.
Issue
Cutis - 96(5)
Issue
Cutis - 96(5)
Page Number
E10-E12
Page Number
E10-E12
Publications
Publications
Article Type
Display Headline
Linear Bluish Black Papules on the Shoulder
Display Headline
Linear Bluish Black Papules on the Shoulder
Legacy Keywords
blue nevus, agminated
Legacy Keywords
blue nevus, agminated
Sections
Questionnaire Body

A 57-year-old woman presented with an asymptomatic, unchanging, 3.5×0.7-cm linear plaque on the right shoulder composed of dozens of clustered, bluish black papules that had been present for several decades. The skin between the papules was unaffected. The patient’s medical and family histories were unremarkable. A deep shave biopsy from the center of the plaque was performed.

 

Disallow All Ads
Alternative CME
Article PDF Media

Sessile Pink Plaque on the Lower Back

Article Type
Changed
Thu, 01/10/2019 - 13:26
Display Headline
Sessile Pink Plaque on the Lower Back

The Diagnosis: Eccrine Poroma

A shave biopsy of the lesion was performed for definitive diagnosis and demonstrated a well-circumscribed tumor with cords and broad columns composed of uniform basaloid cells extending into the dermis and in areas connecting to the overlying epidermis (Figure). There also were small ducts and cysts admixed in the tumor columns that were embedded in a tumor stroma rich in blood vessels. A diagnosis of eccrine poroma was made based on these characteristic histologic features.

 


 

Biopsy revealed a basaloid tumor originating from the epidermis and extending into the dermis (A)(H&E, original magnification ×4). On higher magnification, ducts were evident amongst the tumor cells and a vascular rich stroma was revealed (B)(H&E, original magnification ×10).

First described by Pinkus et al1 in 1956, eccrine poroma is a benign neoplasm of cells from the intraepidermal ductal portion of the eccrine sweat gland. Eccrine poroma (along with hidroacanthoma simplex, dermal duct tumor, and poroid hidradenoma) is one of the poroid neoplasms, which account for approximately 10% of all primary sweat gland tumors.2 Eccrine poroma usually is seen in patients over 40 years of age without any predilection for race or sex.

Characteristically, eccrine poromas clinically manifest as solitary, firm, sharply demarcated papules or nodules that may be sessile or pedunculated and rarely exceed 2 cm in diameter. This entity classically presents on acral, non–hair-bearing areas (eg, palms and soles). Eccrine poromas have a wide range of clinical appearances that can lead to broad differential diagnoses3 and have been described as flesh-colored,3 pink to red,4 purple,5 and pigmented3,4 papules or nodules depending on features such as blood vessel proliferation and pigment deposition.

Eccrine poromas also have been reported on hair-bearing areas of the body, including the head,3 neck,3,6 chest,4,6 hip,7 and pubic area,8 despite the paucity of eccrine glands in these areas on the body. These findings suggest that these neoplasms may not be purely eccrine in origin. The wide range of clinical presentations of eccrine poromas has prompted investigation into further classification and delineation of this neoplasm.3 The occurrence of eccrine poromas on areas of the skin known to have few eccrine glands suggests that eccrine poromas may not be purely comprised of eccrine ducts and instead may be of apocrine origin.3,9,10 Histologic features of eccrine poromas that suggest apocrine origination include sebaceous and follicular differentiation (eg, folliculocentric distribution), the association with the follicular infundibulum, and the presence of follicular germ cells.3,9,10 Thus, apocrine gland involvement in eccrine poromas may account for their appearance in anatomic areas that do not have high concentrations of eccrine glands, such as the trunk and pubic area.

Based on these findings, eccrine poromas may therefore be of eccrine and/or apocrine origin; however, the nomenclature of this neoplasm remains confusing and possibly misleading, as the term eccrine poroma continues to be accepted even in instances in which the differentiation appears to be largely apocrine. The terms poroma and eccrine poroma often are used interchangeably, which contributes to the confusion by failing to acknowledge the possibility of apocrine influence and possibly causing the clinician to exclude eccrine poromas from the differential diagnosis in areas that do not have high concentrations of eccrine glands.

Because of their high degree of clinical variability, characteristic acral location, and misleading nomenclature, eccrine poromas often are mistakenly confused with a long list of other cutaneous neoplasms, including hemangiomas, pyogenic granulomas, melanocytic nevi, warts, cysts, and other adnexal neoplasms.3 In our case, the lesion was abnormally large and was clinically concerning for an unusual sebaceous nevus. Its location on the lower back is not commonly noted and should remind the clinician of the possibility of apocrine differentiation. Clinicians should be aware of the wide phenotypic diversity of eccrine poromas, and therefore they should consider this diagnosis in their differential diagnosis for solitary papules or nodules occurring in any anatomic area.

References
  1. Pinkus H, Rogin JR, Goldman P. Eccrine poroma: tumors exhibiting features of the epidermal sweat duct unit. Arch Dermatol. 1956;74:511-521.
  2. Pylyser K, Dewolf-Peeters C, Marlen K. The histology of eccrine poromas: a study of 14 cases. Dermatologica. 1983;167:243-249.
  3. Moore TO, Orman HL, Orman SK, et al. Poromas of the head and neck. J Am Acad Dermatol. 2001;44:48-52.
  4. Agarwal S, Kumar B, Sharma N. Nodule on the chest. eccrine poroma. Indian J Dermatol Venereol Leprol. 2009;75:639.
  5. Ackerman AB, Abenoza P. Neoplasms With Eccrine Differentiation. Philadelphia, PA: Lea & Febinger; 1990:113-185.
  6. Okun M, Ansell H. Eccrine poroma. report of three cases, two with an unusual location. Arch Dermatol. 1963;88:561-566.
  7. Sarma DP, Zaman SU, Santos EE, et al. Poroma of the hip and buttock. Dermatol Online J. 2009;15:10.
  8. Altamura D, Piccolo D, Lozzi GP, et al. Eccrine poroma in an unusual site: a clinical and dermoscopic simulator of amelanotic melanoma. J Am Acad Dermatol. 2005;53:539-541.
  9. Groben PA, Hitchcock MG, Leshin B, et al. Apocrine poroma, a distinctive case in a patient with nevoid BCC. Am J Dermatopathol. 1992;21:31-33.
  10. Harvell JD, Kerschmann RL, LeBoit PE. Eccrine or apocrine poroma? six poromas with divergent adnexal differentiation. Am J Dermatopathol. 1996;18:1-9.
Article PDF
Author and Disclosure Information

Dr. Marszalek is from Harvard Vanguard Medical Associates, Boston, Massachusetts. Dr. Aung is from the Departments of Pathology and Dermatology, University of Texas MD Anderson Cancer Center, Houston. Dr. Wolpowitz is from Boston Medical Center. Dr. Chen is from the Department of Dermatology, University of Connecticut School of Medicine, Canton.

The authors report no conflict of interest.

Correspondence: Amy Yuntzu-Yen Chen, MD, 117 Albany Turnpike, Canton, CT 06019 ([email protected]).

Issue
Cutis - 96(5)
Publications
Topics
Page Number
E3-E5
Legacy Keywords
Poroma;Eccrine Gland;Apocrine Gland;Adnexal Neoplasm
Sections
Author and Disclosure Information

Dr. Marszalek is from Harvard Vanguard Medical Associates, Boston, Massachusetts. Dr. Aung is from the Departments of Pathology and Dermatology, University of Texas MD Anderson Cancer Center, Houston. Dr. Wolpowitz is from Boston Medical Center. Dr. Chen is from the Department of Dermatology, University of Connecticut School of Medicine, Canton.

The authors report no conflict of interest.

Correspondence: Amy Yuntzu-Yen Chen, MD, 117 Albany Turnpike, Canton, CT 06019 ([email protected]).

Author and Disclosure Information

Dr. Marszalek is from Harvard Vanguard Medical Associates, Boston, Massachusetts. Dr. Aung is from the Departments of Pathology and Dermatology, University of Texas MD Anderson Cancer Center, Houston. Dr. Wolpowitz is from Boston Medical Center. Dr. Chen is from the Department of Dermatology, University of Connecticut School of Medicine, Canton.

The authors report no conflict of interest.

Correspondence: Amy Yuntzu-Yen Chen, MD, 117 Albany Turnpike, Canton, CT 06019 ([email protected]).

Article PDF
Article PDF

The Diagnosis: Eccrine Poroma

A shave biopsy of the lesion was performed for definitive diagnosis and demonstrated a well-circumscribed tumor with cords and broad columns composed of uniform basaloid cells extending into the dermis and in areas connecting to the overlying epidermis (Figure). There also were small ducts and cysts admixed in the tumor columns that were embedded in a tumor stroma rich in blood vessels. A diagnosis of eccrine poroma was made based on these characteristic histologic features.

 


 

Biopsy revealed a basaloid tumor originating from the epidermis and extending into the dermis (A)(H&E, original magnification ×4). On higher magnification, ducts were evident amongst the tumor cells and a vascular rich stroma was revealed (B)(H&E, original magnification ×10).

First described by Pinkus et al1 in 1956, eccrine poroma is a benign neoplasm of cells from the intraepidermal ductal portion of the eccrine sweat gland. Eccrine poroma (along with hidroacanthoma simplex, dermal duct tumor, and poroid hidradenoma) is one of the poroid neoplasms, which account for approximately 10% of all primary sweat gland tumors.2 Eccrine poroma usually is seen in patients over 40 years of age without any predilection for race or sex.

Characteristically, eccrine poromas clinically manifest as solitary, firm, sharply demarcated papules or nodules that may be sessile or pedunculated and rarely exceed 2 cm in diameter. This entity classically presents on acral, non–hair-bearing areas (eg, palms and soles). Eccrine poromas have a wide range of clinical appearances that can lead to broad differential diagnoses3 and have been described as flesh-colored,3 pink to red,4 purple,5 and pigmented3,4 papules or nodules depending on features such as blood vessel proliferation and pigment deposition.

Eccrine poromas also have been reported on hair-bearing areas of the body, including the head,3 neck,3,6 chest,4,6 hip,7 and pubic area,8 despite the paucity of eccrine glands in these areas on the body. These findings suggest that these neoplasms may not be purely eccrine in origin. The wide range of clinical presentations of eccrine poromas has prompted investigation into further classification and delineation of this neoplasm.3 The occurrence of eccrine poromas on areas of the skin known to have few eccrine glands suggests that eccrine poromas may not be purely comprised of eccrine ducts and instead may be of apocrine origin.3,9,10 Histologic features of eccrine poromas that suggest apocrine origination include sebaceous and follicular differentiation (eg, folliculocentric distribution), the association with the follicular infundibulum, and the presence of follicular germ cells.3,9,10 Thus, apocrine gland involvement in eccrine poromas may account for their appearance in anatomic areas that do not have high concentrations of eccrine glands, such as the trunk and pubic area.

Based on these findings, eccrine poromas may therefore be of eccrine and/or apocrine origin; however, the nomenclature of this neoplasm remains confusing and possibly misleading, as the term eccrine poroma continues to be accepted even in instances in which the differentiation appears to be largely apocrine. The terms poroma and eccrine poroma often are used interchangeably, which contributes to the confusion by failing to acknowledge the possibility of apocrine influence and possibly causing the clinician to exclude eccrine poromas from the differential diagnosis in areas that do not have high concentrations of eccrine glands.

Because of their high degree of clinical variability, characteristic acral location, and misleading nomenclature, eccrine poromas often are mistakenly confused with a long list of other cutaneous neoplasms, including hemangiomas, pyogenic granulomas, melanocytic nevi, warts, cysts, and other adnexal neoplasms.3 In our case, the lesion was abnormally large and was clinically concerning for an unusual sebaceous nevus. Its location on the lower back is not commonly noted and should remind the clinician of the possibility of apocrine differentiation. Clinicians should be aware of the wide phenotypic diversity of eccrine poromas, and therefore they should consider this diagnosis in their differential diagnosis for solitary papules or nodules occurring in any anatomic area.

The Diagnosis: Eccrine Poroma

A shave biopsy of the lesion was performed for definitive diagnosis and demonstrated a well-circumscribed tumor with cords and broad columns composed of uniform basaloid cells extending into the dermis and in areas connecting to the overlying epidermis (Figure). There also were small ducts and cysts admixed in the tumor columns that were embedded in a tumor stroma rich in blood vessels. A diagnosis of eccrine poroma was made based on these characteristic histologic features.

 


 

Biopsy revealed a basaloid tumor originating from the epidermis and extending into the dermis (A)(H&E, original magnification ×4). On higher magnification, ducts were evident amongst the tumor cells and a vascular rich stroma was revealed (B)(H&E, original magnification ×10).

First described by Pinkus et al1 in 1956, eccrine poroma is a benign neoplasm of cells from the intraepidermal ductal portion of the eccrine sweat gland. Eccrine poroma (along with hidroacanthoma simplex, dermal duct tumor, and poroid hidradenoma) is one of the poroid neoplasms, which account for approximately 10% of all primary sweat gland tumors.2 Eccrine poroma usually is seen in patients over 40 years of age without any predilection for race or sex.

Characteristically, eccrine poromas clinically manifest as solitary, firm, sharply demarcated papules or nodules that may be sessile or pedunculated and rarely exceed 2 cm in diameter. This entity classically presents on acral, non–hair-bearing areas (eg, palms and soles). Eccrine poromas have a wide range of clinical appearances that can lead to broad differential diagnoses3 and have been described as flesh-colored,3 pink to red,4 purple,5 and pigmented3,4 papules or nodules depending on features such as blood vessel proliferation and pigment deposition.

Eccrine poromas also have been reported on hair-bearing areas of the body, including the head,3 neck,3,6 chest,4,6 hip,7 and pubic area,8 despite the paucity of eccrine glands in these areas on the body. These findings suggest that these neoplasms may not be purely eccrine in origin. The wide range of clinical presentations of eccrine poromas has prompted investigation into further classification and delineation of this neoplasm.3 The occurrence of eccrine poromas on areas of the skin known to have few eccrine glands suggests that eccrine poromas may not be purely comprised of eccrine ducts and instead may be of apocrine origin.3,9,10 Histologic features of eccrine poromas that suggest apocrine origination include sebaceous and follicular differentiation (eg, folliculocentric distribution), the association with the follicular infundibulum, and the presence of follicular germ cells.3,9,10 Thus, apocrine gland involvement in eccrine poromas may account for their appearance in anatomic areas that do not have high concentrations of eccrine glands, such as the trunk and pubic area.

Based on these findings, eccrine poromas may therefore be of eccrine and/or apocrine origin; however, the nomenclature of this neoplasm remains confusing and possibly misleading, as the term eccrine poroma continues to be accepted even in instances in which the differentiation appears to be largely apocrine. The terms poroma and eccrine poroma often are used interchangeably, which contributes to the confusion by failing to acknowledge the possibility of apocrine influence and possibly causing the clinician to exclude eccrine poromas from the differential diagnosis in areas that do not have high concentrations of eccrine glands.

Because of their high degree of clinical variability, characteristic acral location, and misleading nomenclature, eccrine poromas often are mistakenly confused with a long list of other cutaneous neoplasms, including hemangiomas, pyogenic granulomas, melanocytic nevi, warts, cysts, and other adnexal neoplasms.3 In our case, the lesion was abnormally large and was clinically concerning for an unusual sebaceous nevus. Its location on the lower back is not commonly noted and should remind the clinician of the possibility of apocrine differentiation. Clinicians should be aware of the wide phenotypic diversity of eccrine poromas, and therefore they should consider this diagnosis in their differential diagnosis for solitary papules or nodules occurring in any anatomic area.

References
  1. Pinkus H, Rogin JR, Goldman P. Eccrine poroma: tumors exhibiting features of the epidermal sweat duct unit. Arch Dermatol. 1956;74:511-521.
  2. Pylyser K, Dewolf-Peeters C, Marlen K. The histology of eccrine poromas: a study of 14 cases. Dermatologica. 1983;167:243-249.
  3. Moore TO, Orman HL, Orman SK, et al. Poromas of the head and neck. J Am Acad Dermatol. 2001;44:48-52.
  4. Agarwal S, Kumar B, Sharma N. Nodule on the chest. eccrine poroma. Indian J Dermatol Venereol Leprol. 2009;75:639.
  5. Ackerman AB, Abenoza P. Neoplasms With Eccrine Differentiation. Philadelphia, PA: Lea & Febinger; 1990:113-185.
  6. Okun M, Ansell H. Eccrine poroma. report of three cases, two with an unusual location. Arch Dermatol. 1963;88:561-566.
  7. Sarma DP, Zaman SU, Santos EE, et al. Poroma of the hip and buttock. Dermatol Online J. 2009;15:10.
  8. Altamura D, Piccolo D, Lozzi GP, et al. Eccrine poroma in an unusual site: a clinical and dermoscopic simulator of amelanotic melanoma. J Am Acad Dermatol. 2005;53:539-541.
  9. Groben PA, Hitchcock MG, Leshin B, et al. Apocrine poroma, a distinctive case in a patient with nevoid BCC. Am J Dermatopathol. 1992;21:31-33.
  10. Harvell JD, Kerschmann RL, LeBoit PE. Eccrine or apocrine poroma? six poromas with divergent adnexal differentiation. Am J Dermatopathol. 1996;18:1-9.
References
  1. Pinkus H, Rogin JR, Goldman P. Eccrine poroma: tumors exhibiting features of the epidermal sweat duct unit. Arch Dermatol. 1956;74:511-521.
  2. Pylyser K, Dewolf-Peeters C, Marlen K. The histology of eccrine poromas: a study of 14 cases. Dermatologica. 1983;167:243-249.
  3. Moore TO, Orman HL, Orman SK, et al. Poromas of the head and neck. J Am Acad Dermatol. 2001;44:48-52.
  4. Agarwal S, Kumar B, Sharma N. Nodule on the chest. eccrine poroma. Indian J Dermatol Venereol Leprol. 2009;75:639.
  5. Ackerman AB, Abenoza P. Neoplasms With Eccrine Differentiation. Philadelphia, PA: Lea & Febinger; 1990:113-185.
  6. Okun M, Ansell H. Eccrine poroma. report of three cases, two with an unusual location. Arch Dermatol. 1963;88:561-566.
  7. Sarma DP, Zaman SU, Santos EE, et al. Poroma of the hip and buttock. Dermatol Online J. 2009;15:10.
  8. Altamura D, Piccolo D, Lozzi GP, et al. Eccrine poroma in an unusual site: a clinical and dermoscopic simulator of amelanotic melanoma. J Am Acad Dermatol. 2005;53:539-541.
  9. Groben PA, Hitchcock MG, Leshin B, et al. Apocrine poroma, a distinctive case in a patient with nevoid BCC. Am J Dermatopathol. 1992;21:31-33.
  10. Harvell JD, Kerschmann RL, LeBoit PE. Eccrine or apocrine poroma? six poromas with divergent adnexal differentiation. Am J Dermatopathol. 1996;18:1-9.
Issue
Cutis - 96(5)
Issue
Cutis - 96(5)
Page Number
E3-E5
Page Number
E3-E5
Publications
Publications
Topics
Article Type
Display Headline
Sessile Pink Plaque on the Lower Back
Display Headline
Sessile Pink Plaque on the Lower Back
Legacy Keywords
Poroma;Eccrine Gland;Apocrine Gland;Adnexal Neoplasm
Legacy Keywords
Poroma;Eccrine Gland;Apocrine Gland;Adnexal Neoplasm
Sections
Questionnaire Body

A 47-year-old man presented with an asymptomatic, 2.5×1.5-cm, sessile pink plaque with a coalescing papular texture on the lower back of 30 years’ duration. The patient reported that 2 papillated papules with peripheral rims of dark crust had developed in the center of the lesion over the past 6 months. His personal and family histories were unremarkable.

 

Disallow All Ads
Alternative CME
Article PDF Media

Solitary Lesion on the Left Ankle

Article Type
Changed
Thu, 01/10/2019 - 13:26
Display Headline
Solitary Lesion on the Left Ankle

The Diagnosis: Porokeratosis of Mibelli

There are 5 variants of porokeratosis: disseminated superficial actinic porokeratosis (DSAP), linear porokeratosis, porokeratosis of Mibelli, porokeratosis palmaris et plantaris disseminata, and punctate porokeratosis. The most common type is DSAP,1 which is characterized by multiple lesions on the body, particularly in sun-exposed areas. The distinguishing feature of porokeratosis is the cornoid lamella, which is made up of parakeratotic cells extending through the stratum corneum. There also is a thin or absent granular layer beneath it (Figure).2

A punch biopsy of the lesion demonstrated histology that corresponded with disseminated superficial actinic porokeratosis including a characteristic cornoid lamella; however, the clinical diagnosis was determined to be porokeratosis of Mibelli (H&E, original magnification ×200).

Patients generally present in the third and fourth decades of life.1 Risk factors for porokeratosis include sun exposure, immunosuppression, and genetics.2-4 Overexpression of the protein p53 in porokeratosis lesions has been demonstrated in studies investigating the genetics of porokeratosis.5,6 A study of Chinese families with DSAP identified 3 different loci associated with DSAP: DSAP1, DSAP2, and DSAP3.2 The progression to cancer has been noted in all types of porokeratosis lesions. Malignancies include squamous cell carcinoma, Bowen disease, and basal cell carcinoma.7,8

Many treatments have been tried for DSAP including cryotherapy, topical 5-fluorouracil, photodynamic therapy, and topical imiquimod with varying success.1 Our patient was treated with 
cryotherapy but had side effects from treatment including cellulitis and local infections with ulceration before finally healing.

Interestingly, our patient had a single lesion with pathology findings most consistent with DSAP at a later age. Although the pathology suggested DSAP, the size and solitary lesion was more consistent with porokeratosis of Mibelli. Porokeratosis of Mibelli can occur concurrently with DSAP,9 but we have not seen other lesions in this patient. We have educated our patient to be aware of other lesions that may occur in the future. Due to risk for malignant conversion, it is generally viewed as beneficial to treat patients who present with porokeratosis lesions. Our patient’s lesion ultimately cleared and he has not developed new lesions at 1-year follow-up.

Although DSAP generally presents in the third and fourth decades of life and porokeratosis of Mibelli during childhood, it is important to educate both dermatologists and primary care physicians to be aware of the possibility of both diagnoses in the elderly population.

References
  1. Rouhani P, Fischer M, Meehan S, et al. Disseminated superficial actinic porokeratosis. Dermatol Online J. 2012;18:24.
  2. Murase J, Gilliam AC, et al. Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: update on the genetics and clinical expression of porokeratosis. J Am Acad 
Dermatol. 2010;63:886-891.
  3. Lederman JS, Sober AJ, Lederman GS. Immunosuppression: a cause of porokeratosis? J Am Acad Dermatol. 1985;13:75-79.
  4. Hernandez MH, Lai CH, Mallory SB. Disseminated porokeratosis associated with chronic renal failure: a new type of disseminated porokeratosis? Arch Dermatol. 2000;136:1568-1569.
  5. Magee JW, McCalmont TH, LeBoit PE. Overexpression of p53 tumor suppressor protein in porokeratosis. Arch Dermatol. 1994;130:187-190.
  6. Arranz-Salas I, Sanz-Trelles A, Ojeda DB. p53 alterations in porokeratosis. J Cutan Pathol. 2003;30:455-458.
  7. Curnow P, Foley P, Baker C. Multiple squamous cell carcinomas complicating linear porokeratosis. Australas J Dermatol. 2003;44:136-139.
  8. Lee HR, Han TY, Son SJ, et al. Squamous cell carcinoma developing within lesions of disseminated superficial actinic porokeratosis. Ann Dermatol. 2011;23:536-538.
  9. Mehta V, Balachandran C. Simultaneous co-occurrence of porokeratosis of Mibelli with disseminated superficial actinic porokeratosis. Indian J Dermatol. 2009;54:390-391.
Article PDF
Author and Disclosure Information

Both from Northeast Ohio Medical University, Rootstown. Dr. Mostow also is from Case Western Reserve University School of Medicine, Cleveland, Ohio.


The authors report no conflict of interest.


Correspondence: Eliot N. Mostow, MD, 566 White Pond Dr, Ste E, Akron, OH 44320 ([email protected]).

Issue
Cutis - 96(4)
Publications
Topics
Page Number
E13-E15
Legacy Keywords
disseminated superficial actinic porokeratosis, DSAP, porokeratosis of Mibelli
Sections
Author and Disclosure Information

Both from Northeast Ohio Medical University, Rootstown. Dr. Mostow also is from Case Western Reserve University School of Medicine, Cleveland, Ohio.


The authors report no conflict of interest.


Correspondence: Eliot N. Mostow, MD, 566 White Pond Dr, Ste E, Akron, OH 44320 ([email protected]).

Author and Disclosure Information

Both from Northeast Ohio Medical University, Rootstown. Dr. Mostow also is from Case Western Reserve University School of Medicine, Cleveland, Ohio.


The authors report no conflict of interest.


Correspondence: Eliot N. Mostow, MD, 566 White Pond Dr, Ste E, Akron, OH 44320 ([email protected]).

Article PDF
Article PDF

The Diagnosis: Porokeratosis of Mibelli

There are 5 variants of porokeratosis: disseminated superficial actinic porokeratosis (DSAP), linear porokeratosis, porokeratosis of Mibelli, porokeratosis palmaris et plantaris disseminata, and punctate porokeratosis. The most common type is DSAP,1 which is characterized by multiple lesions on the body, particularly in sun-exposed areas. The distinguishing feature of porokeratosis is the cornoid lamella, which is made up of parakeratotic cells extending through the stratum corneum. There also is a thin or absent granular layer beneath it (Figure).2

A punch biopsy of the lesion demonstrated histology that corresponded with disseminated superficial actinic porokeratosis including a characteristic cornoid lamella; however, the clinical diagnosis was determined to be porokeratosis of Mibelli (H&E, original magnification ×200).

Patients generally present in the third and fourth decades of life.1 Risk factors for porokeratosis include sun exposure, immunosuppression, and genetics.2-4 Overexpression of the protein p53 in porokeratosis lesions has been demonstrated in studies investigating the genetics of porokeratosis.5,6 A study of Chinese families with DSAP identified 3 different loci associated with DSAP: DSAP1, DSAP2, and DSAP3.2 The progression to cancer has been noted in all types of porokeratosis lesions. Malignancies include squamous cell carcinoma, Bowen disease, and basal cell carcinoma.7,8

Many treatments have been tried for DSAP including cryotherapy, topical 5-fluorouracil, photodynamic therapy, and topical imiquimod with varying success.1 Our patient was treated with 
cryotherapy but had side effects from treatment including cellulitis and local infections with ulceration before finally healing.

Interestingly, our patient had a single lesion with pathology findings most consistent with DSAP at a later age. Although the pathology suggested DSAP, the size and solitary lesion was more consistent with porokeratosis of Mibelli. Porokeratosis of Mibelli can occur concurrently with DSAP,9 but we have not seen other lesions in this patient. We have educated our patient to be aware of other lesions that may occur in the future. Due to risk for malignant conversion, it is generally viewed as beneficial to treat patients who present with porokeratosis lesions. Our patient’s lesion ultimately cleared and he has not developed new lesions at 1-year follow-up.

Although DSAP generally presents in the third and fourth decades of life and porokeratosis of Mibelli during childhood, it is important to educate both dermatologists and primary care physicians to be aware of the possibility of both diagnoses in the elderly population.

The Diagnosis: Porokeratosis of Mibelli

There are 5 variants of porokeratosis: disseminated superficial actinic porokeratosis (DSAP), linear porokeratosis, porokeratosis of Mibelli, porokeratosis palmaris et plantaris disseminata, and punctate porokeratosis. The most common type is DSAP,1 which is characterized by multiple lesions on the body, particularly in sun-exposed areas. The distinguishing feature of porokeratosis is the cornoid lamella, which is made up of parakeratotic cells extending through the stratum corneum. There also is a thin or absent granular layer beneath it (Figure).2

A punch biopsy of the lesion demonstrated histology that corresponded with disseminated superficial actinic porokeratosis including a characteristic cornoid lamella; however, the clinical diagnosis was determined to be porokeratosis of Mibelli (H&E, original magnification ×200).

Patients generally present in the third and fourth decades of life.1 Risk factors for porokeratosis include sun exposure, immunosuppression, and genetics.2-4 Overexpression of the protein p53 in porokeratosis lesions has been demonstrated in studies investigating the genetics of porokeratosis.5,6 A study of Chinese families with DSAP identified 3 different loci associated with DSAP: DSAP1, DSAP2, and DSAP3.2 The progression to cancer has been noted in all types of porokeratosis lesions. Malignancies include squamous cell carcinoma, Bowen disease, and basal cell carcinoma.7,8

Many treatments have been tried for DSAP including cryotherapy, topical 5-fluorouracil, photodynamic therapy, and topical imiquimod with varying success.1 Our patient was treated with 
cryotherapy but had side effects from treatment including cellulitis and local infections with ulceration before finally healing.

Interestingly, our patient had a single lesion with pathology findings most consistent with DSAP at a later age. Although the pathology suggested DSAP, the size and solitary lesion was more consistent with porokeratosis of Mibelli. Porokeratosis of Mibelli can occur concurrently with DSAP,9 but we have not seen other lesions in this patient. We have educated our patient to be aware of other lesions that may occur in the future. Due to risk for malignant conversion, it is generally viewed as beneficial to treat patients who present with porokeratosis lesions. Our patient’s lesion ultimately cleared and he has not developed new lesions at 1-year follow-up.

Although DSAP generally presents in the third and fourth decades of life and porokeratosis of Mibelli during childhood, it is important to educate both dermatologists and primary care physicians to be aware of the possibility of both diagnoses in the elderly population.

References
  1. Rouhani P, Fischer M, Meehan S, et al. Disseminated superficial actinic porokeratosis. Dermatol Online J. 2012;18:24.
  2. Murase J, Gilliam AC, et al. Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: update on the genetics and clinical expression of porokeratosis. J Am Acad 
Dermatol. 2010;63:886-891.
  3. Lederman JS, Sober AJ, Lederman GS. Immunosuppression: a cause of porokeratosis? J Am Acad Dermatol. 1985;13:75-79.
  4. Hernandez MH, Lai CH, Mallory SB. Disseminated porokeratosis associated with chronic renal failure: a new type of disseminated porokeratosis? Arch Dermatol. 2000;136:1568-1569.
  5. Magee JW, McCalmont TH, LeBoit PE. Overexpression of p53 tumor suppressor protein in porokeratosis. Arch Dermatol. 1994;130:187-190.
  6. Arranz-Salas I, Sanz-Trelles A, Ojeda DB. p53 alterations in porokeratosis. J Cutan Pathol. 2003;30:455-458.
  7. Curnow P, Foley P, Baker C. Multiple squamous cell carcinomas complicating linear porokeratosis. Australas J Dermatol. 2003;44:136-139.
  8. Lee HR, Han TY, Son SJ, et al. Squamous cell carcinoma developing within lesions of disseminated superficial actinic porokeratosis. Ann Dermatol. 2011;23:536-538.
  9. Mehta V, Balachandran C. Simultaneous co-occurrence of porokeratosis of Mibelli with disseminated superficial actinic porokeratosis. Indian J Dermatol. 2009;54:390-391.
References
  1. Rouhani P, Fischer M, Meehan S, et al. Disseminated superficial actinic porokeratosis. Dermatol Online J. 2012;18:24.
  2. Murase J, Gilliam AC, et al. Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: update on the genetics and clinical expression of porokeratosis. J Am Acad 
Dermatol. 2010;63:886-891.
  3. Lederman JS, Sober AJ, Lederman GS. Immunosuppression: a cause of porokeratosis? J Am Acad Dermatol. 1985;13:75-79.
  4. Hernandez MH, Lai CH, Mallory SB. Disseminated porokeratosis associated with chronic renal failure: a new type of disseminated porokeratosis? Arch Dermatol. 2000;136:1568-1569.
  5. Magee JW, McCalmont TH, LeBoit PE. Overexpression of p53 tumor suppressor protein in porokeratosis. Arch Dermatol. 1994;130:187-190.
  6. Arranz-Salas I, Sanz-Trelles A, Ojeda DB. p53 alterations in porokeratosis. J Cutan Pathol. 2003;30:455-458.
  7. Curnow P, Foley P, Baker C. Multiple squamous cell carcinomas complicating linear porokeratosis. Australas J Dermatol. 2003;44:136-139.
  8. Lee HR, Han TY, Son SJ, et al. Squamous cell carcinoma developing within lesions of disseminated superficial actinic porokeratosis. Ann Dermatol. 2011;23:536-538.
  9. Mehta V, Balachandran C. Simultaneous co-occurrence of porokeratosis of Mibelli with disseminated superficial actinic porokeratosis. Indian J Dermatol. 2009;54:390-391.
Issue
Cutis - 96(4)
Issue
Cutis - 96(4)
Page Number
E13-E15
Page Number
E13-E15
Publications
Publications
Topics
Article Type
Display Headline
Solitary Lesion on the Left Ankle
Display Headline
Solitary Lesion on the Left Ankle
Legacy Keywords
disseminated superficial actinic porokeratosis, DSAP, porokeratosis of Mibelli
Legacy Keywords
disseminated superficial actinic porokeratosis, DSAP, porokeratosis of Mibelli
Sections
Questionnaire Body

A punch biopsy of the lesion demonstrated histology that corresponded with DSAP including a characteristic coronoid lamella. However, the clinical diagnosis was determined to be porokeratosis of Mibelli.

A 69-year-old white man presented with a solitary lesion on the left ankle. His medical history included hypertension and arthritis. He resided in Florida for 11 years but denied tanning and has had sensitive skin throughout his life. He had no other notable skin conditions, except for nummular eczema. He did not have a family history of skin cancer. Physical examination showed the single lesion on the left ankle.

 

Disallow All Ads
Alternative CME
Article PDF Media

What Is Your Diagnosis? Fixed Cutaneous Sporotrichosis

Article Type
Changed
Thu, 01/10/2019 - 13:26
Display Headline
What Is Your Diagnosis? Fixed Cutaneous Sporotrichosis

The Diagnosis: Fixed Cutaneous Sporotrichosis

On further questioning at our dermatology clinic, the patient reported having landed face-first into rocks and gravel during the all-terrain vehicle accident. After his medical history was noted and a physical examination was completed, bacterial and fungal cultures of the wound were taken. The fungal culture was positive for Sporothrix schenckii. The patient was prescribed itraconazole 200 mg 3 times daily for 3 days, then 200 mg twice daily for an additional 4 weeks after the lesions completely resolved. An ophthalmologist was immediately consulted to rule out sinus and periorbital involvement. After computed tomography revealed possible preseptal cellulitis with frontal sinus involvement, the patient was admitted and intravenous amphotericin B was administered. Following consultations with infectious disease specialists and radiologists, amphotericin B was discontinued and the patient was discharged on itraconazole 200 mg twice daily with close monitoring. At 3-month follow-up, the sporotrichosis infection had completely cleared (Figure).

Sporotrichosis infection 3 months after treatment with itraconazole 200 mg twice daily.

Deep fungal infections comprise 2 distinct groups: systemic and subcutaneous mycoses. Individuals with subcutaneous mycoses present with skin involvement as the primary feature. Sporotrichosis is the most common cause of this type of mycosis1 and is caused by the dimorphic fungus S schenckii, an environmental saprophyte often residing in soil. Sporothrix schenckii exists as mold in a natural environment but exists as yeast in host tissue, thus causing ensuing infection.

Epidemiology

Sporotrichosis occurs worldwide but most frequently in temperate tropical and subtropical regions. The majority of cases are reported in Mexico and Central and South America1; however, cases have been seen in the southern United States, Japan, and Australia.2 In the United States, sporotrichosis is most commonly found in river valleys of the Midwest.

Sporothrix schenckii is most commonly isolated in hay, sphagnum moss, thorny plants, and soil, but it also has been described in other manifold host environments. Unusual origins of inoculation include an old and rust-stained camping tent in Mexico,3 crawl space joists of a house in Indiana,4 and hay bales used as props in a haunted house in Oklahoma.5

The incidence of infection is primarily sporadic; however, outbreaks among individuals who share a common environment favorable for the growth of S schenckii are at risk. Those identified to be at risk include rose gardeners, berry pickers, those who work in tree nurseries, horticulturists, landscapers, and miners.

Pathogenesis

As a dimorphic fungus, infection occurs when a conidium in the mold phase is introduced into the skin, usually by traumatic skin injury, and is 
converted to the yeast form in vivo. Distribution of infection by this organism is most commonly 
localized to the cutaneous, subcutaneous, and lymphocutaneous regions in healthy hosts but can involve visceral and osteoarticular structures in immunocompromised hosts.1,6 Pulmonary and disseminated forms are rare but can occur when 
S schenckii conidia are inhaled. Zoonotic transmission of the fungus also can occur with exposure to infected animals. Sporothrix schenckii has been reported to occur in cats, dogs, horses, donkeys, squirrels, armadillos, and dolphins.7-11

Pathology

Sporothrix schenckii is typically not visualized on microscopic examination due to the small number of microorganisms present; however, cultures grow rapidly 
(3–5 days) on Sabouraud agar. The fungus most commonly develops as white or off-white compact colonies that progressively darken with age, transitioning to gray and then black.1 Microscopically, the hyphae produce oval or pyriform conidia, which are assembled 
in a typical bouquetlike manner. Conversion of the organism to yeast on enriched medium such as brain-heart infusion agar or blood-cysteine-glucose agar confirms the diagnosis.

Acute lesions typically show a nonspecific mixed infiltrate, but established lesions may reveal granulomatous formation and neutrophilic microabscesses.1,2 Asteroid bodies, which are cigar-shaped yeasts surrounded by eosinophilic coronae radiata, may be found. Organisms are sparsely distributed within the lesions, necessitating a thorough examination of the culture for identification.

Clinical Features

Sporotrichosis has 3 main classifications: lymphocutaneous, fixed cutaneous, and disseminated. Lymphocutaneous sporotrichosis is the most common form of the infection.2 The disease presents with a small indurated papule occurring approximately 7 to 30 days after inoculation into the skin. The papule slowly enlarges, forms a nodule, and then frequently ulcerates. Over time, draining lymphatics become edematous and inflammatory, and a chain of secondary nodules begins to appear proximal to the initial lesion. The primary and secondary nodules may continue to ulcerate; alternately, they may heal or become chronic.

In fixed cutaneous sporotrichosis, the infection remains localized to one region and a granuloma may develop, which also may ulcerate. Satellite nodules may appear along the periphery of the lesion. Lymphatic spread is not observed in this form of 
the disease.

The disseminated form is a result of hematogenous spread from the primary inoculation site and typically occurs in an immunocompromised host. This form can present as pulmonary disease, sinusitis, and meningitis.1

Differential Diagnosis

The differential diagnosis for sporotrichosis includes atypical mycobacteria, nocardiosis, blastomycosis, pyogenic bacteria, leishmaniasis, tularemia, 
and tuberculosis.

Treatment

Treatment of sporotrichosis is always required. A saturated solution of potassium iodide has classically been used; however, it is frequently associated with side effects and can be problematic to administer.12 Given its low cost and traditional efficacy, it may still be used in some parts of the world.

Currently, the treatment of choice for fixed cutaneous and lymphocutaneous sporotrichosis is itraconazole 100 to 200 mg once daily for 3 to 6 months.1 The recommended treatment of osteoarticular sporotrichosis is itraconazole, but prolonged therapy is required.

Heat therapy is an alternative treatment option, as certain strains of S schenckii do not grow at temperatures higher than 35°C. Hot compresses must be used for at least 1 hour a day for several months, which may affect patient compliance.

Immunocompromised patients often have disseminated infection and require lifelong suppressive therapy with itraconazole and may require initial treatment with amphotericin B.13

Conclusion

Subcutaneous sporotrichosis can develop in patients with a traumatic injury involving vegetation, soil, or animals. Although some patients may develop more invasive disease, most infections in immunocompetent patients will resolve after 3 to 6 months of itraconazole 100 to 200 mg once daily.1

References
  1. De Araujo T, Marques AC, Kerdel F. Sporotrichosis. Int J 
Dermatol. 2001;40:737-742.
  2. Freedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick’s 
Dermatology in General Medicine. Vol 2. 6th ed. New York, NY: McGraw-Hill; 2003.
  3. Campos P, Arenas R, Coronado H. Epidemic cutaneous sporotrichosis. Int J Dermatol. 1994;33:38-41.
  4. Dillon GP, Lehmann PF, Talanin NY. Handyperson’s hazard: crawl space sporotrichosis. JAMA. 1995;274: 
1673-1674.
  5. Dooley DP, Bostic PS, Beckius ML. Spook house sporotrichosis: a point-source outbreak of sporotrichosis associated with hay bale props in a Halloween haunted house. Arch Int Med. 1997;157:1885-1887.
  6. Kauffman CA. Sporotrichosis. Clin Infect Dis. 1999;29:231-236.
  7. Migaki G, Font RL, Kaplan W, et al. Sporotrichosis in a Pacific white-sided dolphin (Lagenorhynchus obliquidens). Am J Vet Res. 1978;39:1916-1919.
  8. Crothers SL, White SD, Ihrke PJ, et al. Sporotrichosis: a retrospective evaluation of 23 cases seen in northern California (1987-2007). Vet Dermatol. 2009;20:249-259.
  9. Saravanakumar PS, Eslami P, Zar FA. Lymphocutaneous 
sporotrichosis associated with a squirrel bite: case reports and review. Clin Infect Dis. 1996;23:647-648.
  10. Wenker CJ, Kaufman L, Bacciarini LN, et al. Sporotrichosis in a nine-banded armadillo (Dasypus novemcinctus). J Zoo Wildl Med. 1998;29:474-478.
  11. Barros MB, Schubach Ade O, do Valle AC, et al. 
Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis. 2004;38:529-535.
  12. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis. 1995;21:981-985.
  13. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the managements of patients with sporotrichosis. Clin Infect Dis. 2000;30:684-687.
Article PDF
Author and Disclosure Information

Dr. Fulghum is from University of Oklahoma-Tulsa School of Community Medicine. Drs. Mollet and Nguyen are from University of Oklahoma Health Sciences Center, Tulsa.


The authors report no conflict of interest.


Correspondence: Kelley Fulghum, MD ([email protected]).

Issue
Cutis - 96(4)
Publications
Topics
Page Number
218, 227-228
Legacy Keywords
pediatric dermatology, nodules on the cheek, periocular, midfacial avulsion, Sporothrix schenckii, sporotrichosis, fungal infection, subcutaneous mycosis, environmental dermatology
Sections
Author and Disclosure Information

Dr. Fulghum is from University of Oklahoma-Tulsa School of Community Medicine. Drs. Mollet and Nguyen are from University of Oklahoma Health Sciences Center, Tulsa.


The authors report no conflict of interest.


Correspondence: Kelley Fulghum, MD ([email protected]).

Author and Disclosure Information

Dr. Fulghum is from University of Oklahoma-Tulsa School of Community Medicine. Drs. Mollet and Nguyen are from University of Oklahoma Health Sciences Center, Tulsa.


The authors report no conflict of interest.


Correspondence: Kelley Fulghum, MD ([email protected]).

Article PDF
Article PDF
Related Articles

The Diagnosis: Fixed Cutaneous Sporotrichosis

On further questioning at our dermatology clinic, the patient reported having landed face-first into rocks and gravel during the all-terrain vehicle accident. After his medical history was noted and a physical examination was completed, bacterial and fungal cultures of the wound were taken. The fungal culture was positive for Sporothrix schenckii. The patient was prescribed itraconazole 200 mg 3 times daily for 3 days, then 200 mg twice daily for an additional 4 weeks after the lesions completely resolved. An ophthalmologist was immediately consulted to rule out sinus and periorbital involvement. After computed tomography revealed possible preseptal cellulitis with frontal sinus involvement, the patient was admitted and intravenous amphotericin B was administered. Following consultations with infectious disease specialists and radiologists, amphotericin B was discontinued and the patient was discharged on itraconazole 200 mg twice daily with close monitoring. At 3-month follow-up, the sporotrichosis infection had completely cleared (Figure).

Sporotrichosis infection 3 months after treatment with itraconazole 200 mg twice daily.

Deep fungal infections comprise 2 distinct groups: systemic and subcutaneous mycoses. Individuals with subcutaneous mycoses present with skin involvement as the primary feature. Sporotrichosis is the most common cause of this type of mycosis1 and is caused by the dimorphic fungus S schenckii, an environmental saprophyte often residing in soil. Sporothrix schenckii exists as mold in a natural environment but exists as yeast in host tissue, thus causing ensuing infection.

Epidemiology

Sporotrichosis occurs worldwide but most frequently in temperate tropical and subtropical regions. The majority of cases are reported in Mexico and Central and South America1; however, cases have been seen in the southern United States, Japan, and Australia.2 In the United States, sporotrichosis is most commonly found in river valleys of the Midwest.

Sporothrix schenckii is most commonly isolated in hay, sphagnum moss, thorny plants, and soil, but it also has been described in other manifold host environments. Unusual origins of inoculation include an old and rust-stained camping tent in Mexico,3 crawl space joists of a house in Indiana,4 and hay bales used as props in a haunted house in Oklahoma.5

The incidence of infection is primarily sporadic; however, outbreaks among individuals who share a common environment favorable for the growth of S schenckii are at risk. Those identified to be at risk include rose gardeners, berry pickers, those who work in tree nurseries, horticulturists, landscapers, and miners.

Pathogenesis

As a dimorphic fungus, infection occurs when a conidium in the mold phase is introduced into the skin, usually by traumatic skin injury, and is 
converted to the yeast form in vivo. Distribution of infection by this organism is most commonly 
localized to the cutaneous, subcutaneous, and lymphocutaneous regions in healthy hosts but can involve visceral and osteoarticular structures in immunocompromised hosts.1,6 Pulmonary and disseminated forms are rare but can occur when 
S schenckii conidia are inhaled. Zoonotic transmission of the fungus also can occur with exposure to infected animals. Sporothrix schenckii has been reported to occur in cats, dogs, horses, donkeys, squirrels, armadillos, and dolphins.7-11

Pathology

Sporothrix schenckii is typically not visualized on microscopic examination due to the small number of microorganisms present; however, cultures grow rapidly 
(3–5 days) on Sabouraud agar. The fungus most commonly develops as white or off-white compact colonies that progressively darken with age, transitioning to gray and then black.1 Microscopically, the hyphae produce oval or pyriform conidia, which are assembled 
in a typical bouquetlike manner. Conversion of the organism to yeast on enriched medium such as brain-heart infusion agar or blood-cysteine-glucose agar confirms the diagnosis.

Acute lesions typically show a nonspecific mixed infiltrate, but established lesions may reveal granulomatous formation and neutrophilic microabscesses.1,2 Asteroid bodies, which are cigar-shaped yeasts surrounded by eosinophilic coronae radiata, may be found. Organisms are sparsely distributed within the lesions, necessitating a thorough examination of the culture for identification.

Clinical Features

Sporotrichosis has 3 main classifications: lymphocutaneous, fixed cutaneous, and disseminated. Lymphocutaneous sporotrichosis is the most common form of the infection.2 The disease presents with a small indurated papule occurring approximately 7 to 30 days after inoculation into the skin. The papule slowly enlarges, forms a nodule, and then frequently ulcerates. Over time, draining lymphatics become edematous and inflammatory, and a chain of secondary nodules begins to appear proximal to the initial lesion. The primary and secondary nodules may continue to ulcerate; alternately, they may heal or become chronic.

In fixed cutaneous sporotrichosis, the infection remains localized to one region and a granuloma may develop, which also may ulcerate. Satellite nodules may appear along the periphery of the lesion. Lymphatic spread is not observed in this form of 
the disease.

The disseminated form is a result of hematogenous spread from the primary inoculation site and typically occurs in an immunocompromised host. This form can present as pulmonary disease, sinusitis, and meningitis.1

Differential Diagnosis

The differential diagnosis for sporotrichosis includes atypical mycobacteria, nocardiosis, blastomycosis, pyogenic bacteria, leishmaniasis, tularemia, 
and tuberculosis.

Treatment

Treatment of sporotrichosis is always required. A saturated solution of potassium iodide has classically been used; however, it is frequently associated with side effects and can be problematic to administer.12 Given its low cost and traditional efficacy, it may still be used in some parts of the world.

Currently, the treatment of choice for fixed cutaneous and lymphocutaneous sporotrichosis is itraconazole 100 to 200 mg once daily for 3 to 6 months.1 The recommended treatment of osteoarticular sporotrichosis is itraconazole, but prolonged therapy is required.

Heat therapy is an alternative treatment option, as certain strains of S schenckii do not grow at temperatures higher than 35°C. Hot compresses must be used for at least 1 hour a day for several months, which may affect patient compliance.

Immunocompromised patients often have disseminated infection and require lifelong suppressive therapy with itraconazole and may require initial treatment with amphotericin B.13

Conclusion

Subcutaneous sporotrichosis can develop in patients with a traumatic injury involving vegetation, soil, or animals. Although some patients may develop more invasive disease, most infections in immunocompetent patients will resolve after 3 to 6 months of itraconazole 100 to 200 mg once daily.1

The Diagnosis: Fixed Cutaneous Sporotrichosis

On further questioning at our dermatology clinic, the patient reported having landed face-first into rocks and gravel during the all-terrain vehicle accident. After his medical history was noted and a physical examination was completed, bacterial and fungal cultures of the wound were taken. The fungal culture was positive for Sporothrix schenckii. The patient was prescribed itraconazole 200 mg 3 times daily for 3 days, then 200 mg twice daily for an additional 4 weeks after the lesions completely resolved. An ophthalmologist was immediately consulted to rule out sinus and periorbital involvement. After computed tomography revealed possible preseptal cellulitis with frontal sinus involvement, the patient was admitted and intravenous amphotericin B was administered. Following consultations with infectious disease specialists and radiologists, amphotericin B was discontinued and the patient was discharged on itraconazole 200 mg twice daily with close monitoring. At 3-month follow-up, the sporotrichosis infection had completely cleared (Figure).

Sporotrichosis infection 3 months after treatment with itraconazole 200 mg twice daily.

Deep fungal infections comprise 2 distinct groups: systemic and subcutaneous mycoses. Individuals with subcutaneous mycoses present with skin involvement as the primary feature. Sporotrichosis is the most common cause of this type of mycosis1 and is caused by the dimorphic fungus S schenckii, an environmental saprophyte often residing in soil. Sporothrix schenckii exists as mold in a natural environment but exists as yeast in host tissue, thus causing ensuing infection.

Epidemiology

Sporotrichosis occurs worldwide but most frequently in temperate tropical and subtropical regions. The majority of cases are reported in Mexico and Central and South America1; however, cases have been seen in the southern United States, Japan, and Australia.2 In the United States, sporotrichosis is most commonly found in river valleys of the Midwest.

Sporothrix schenckii is most commonly isolated in hay, sphagnum moss, thorny plants, and soil, but it also has been described in other manifold host environments. Unusual origins of inoculation include an old and rust-stained camping tent in Mexico,3 crawl space joists of a house in Indiana,4 and hay bales used as props in a haunted house in Oklahoma.5

The incidence of infection is primarily sporadic; however, outbreaks among individuals who share a common environment favorable for the growth of S schenckii are at risk. Those identified to be at risk include rose gardeners, berry pickers, those who work in tree nurseries, horticulturists, landscapers, and miners.

Pathogenesis

As a dimorphic fungus, infection occurs when a conidium in the mold phase is introduced into the skin, usually by traumatic skin injury, and is 
converted to the yeast form in vivo. Distribution of infection by this organism is most commonly 
localized to the cutaneous, subcutaneous, and lymphocutaneous regions in healthy hosts but can involve visceral and osteoarticular structures in immunocompromised hosts.1,6 Pulmonary and disseminated forms are rare but can occur when 
S schenckii conidia are inhaled. Zoonotic transmission of the fungus also can occur with exposure to infected animals. Sporothrix schenckii has been reported to occur in cats, dogs, horses, donkeys, squirrels, armadillos, and dolphins.7-11

Pathology

Sporothrix schenckii is typically not visualized on microscopic examination due to the small number of microorganisms present; however, cultures grow rapidly 
(3–5 days) on Sabouraud agar. The fungus most commonly develops as white or off-white compact colonies that progressively darken with age, transitioning to gray and then black.1 Microscopically, the hyphae produce oval or pyriform conidia, which are assembled 
in a typical bouquetlike manner. Conversion of the organism to yeast on enriched medium such as brain-heart infusion agar or blood-cysteine-glucose agar confirms the diagnosis.

Acute lesions typically show a nonspecific mixed infiltrate, but established lesions may reveal granulomatous formation and neutrophilic microabscesses.1,2 Asteroid bodies, which are cigar-shaped yeasts surrounded by eosinophilic coronae radiata, may be found. Organisms are sparsely distributed within the lesions, necessitating a thorough examination of the culture for identification.

Clinical Features

Sporotrichosis has 3 main classifications: lymphocutaneous, fixed cutaneous, and disseminated. Lymphocutaneous sporotrichosis is the most common form of the infection.2 The disease presents with a small indurated papule occurring approximately 7 to 30 days after inoculation into the skin. The papule slowly enlarges, forms a nodule, and then frequently ulcerates. Over time, draining lymphatics become edematous and inflammatory, and a chain of secondary nodules begins to appear proximal to the initial lesion. The primary and secondary nodules may continue to ulcerate; alternately, they may heal or become chronic.

In fixed cutaneous sporotrichosis, the infection remains localized to one region and a granuloma may develop, which also may ulcerate. Satellite nodules may appear along the periphery of the lesion. Lymphatic spread is not observed in this form of 
the disease.

The disseminated form is a result of hematogenous spread from the primary inoculation site and typically occurs in an immunocompromised host. This form can present as pulmonary disease, sinusitis, and meningitis.1

Differential Diagnosis

The differential diagnosis for sporotrichosis includes atypical mycobacteria, nocardiosis, blastomycosis, pyogenic bacteria, leishmaniasis, tularemia, 
and tuberculosis.

Treatment

Treatment of sporotrichosis is always required. A saturated solution of potassium iodide has classically been used; however, it is frequently associated with side effects and can be problematic to administer.12 Given its low cost and traditional efficacy, it may still be used in some parts of the world.

Currently, the treatment of choice for fixed cutaneous and lymphocutaneous sporotrichosis is itraconazole 100 to 200 mg once daily for 3 to 6 months.1 The recommended treatment of osteoarticular sporotrichosis is itraconazole, but prolonged therapy is required.

Heat therapy is an alternative treatment option, as certain strains of S schenckii do not grow at temperatures higher than 35°C. Hot compresses must be used for at least 1 hour a day for several months, which may affect patient compliance.

Immunocompromised patients often have disseminated infection and require lifelong suppressive therapy with itraconazole and may require initial treatment with amphotericin B.13

Conclusion

Subcutaneous sporotrichosis can develop in patients with a traumatic injury involving vegetation, soil, or animals. Although some patients may develop more invasive disease, most infections in immunocompetent patients will resolve after 3 to 6 months of itraconazole 100 to 200 mg once daily.1

References
  1. De Araujo T, Marques AC, Kerdel F. Sporotrichosis. Int J 
Dermatol. 2001;40:737-742.
  2. Freedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick’s 
Dermatology in General Medicine. Vol 2. 6th ed. New York, NY: McGraw-Hill; 2003.
  3. Campos P, Arenas R, Coronado H. Epidemic cutaneous sporotrichosis. Int J Dermatol. 1994;33:38-41.
  4. Dillon GP, Lehmann PF, Talanin NY. Handyperson’s hazard: crawl space sporotrichosis. JAMA. 1995;274: 
1673-1674.
  5. Dooley DP, Bostic PS, Beckius ML. Spook house sporotrichosis: a point-source outbreak of sporotrichosis associated with hay bale props in a Halloween haunted house. Arch Int Med. 1997;157:1885-1887.
  6. Kauffman CA. Sporotrichosis. Clin Infect Dis. 1999;29:231-236.
  7. Migaki G, Font RL, Kaplan W, et al. Sporotrichosis in a Pacific white-sided dolphin (Lagenorhynchus obliquidens). Am J Vet Res. 1978;39:1916-1919.
  8. Crothers SL, White SD, Ihrke PJ, et al. Sporotrichosis: a retrospective evaluation of 23 cases seen in northern California (1987-2007). Vet Dermatol. 2009;20:249-259.
  9. Saravanakumar PS, Eslami P, Zar FA. Lymphocutaneous 
sporotrichosis associated with a squirrel bite: case reports and review. Clin Infect Dis. 1996;23:647-648.
  10. Wenker CJ, Kaufman L, Bacciarini LN, et al. Sporotrichosis in a nine-banded armadillo (Dasypus novemcinctus). J Zoo Wildl Med. 1998;29:474-478.
  11. Barros MB, Schubach Ade O, do Valle AC, et al. 
Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis. 2004;38:529-535.
  12. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis. 1995;21:981-985.
  13. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the managements of patients with sporotrichosis. Clin Infect Dis. 2000;30:684-687.
References
  1. De Araujo T, Marques AC, Kerdel F. Sporotrichosis. Int J 
Dermatol. 2001;40:737-742.
  2. Freedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick’s 
Dermatology in General Medicine. Vol 2. 6th ed. New York, NY: McGraw-Hill; 2003.
  3. Campos P, Arenas R, Coronado H. Epidemic cutaneous sporotrichosis. Int J Dermatol. 1994;33:38-41.
  4. Dillon GP, Lehmann PF, Talanin NY. Handyperson’s hazard: crawl space sporotrichosis. JAMA. 1995;274: 
1673-1674.
  5. Dooley DP, Bostic PS, Beckius ML. Spook house sporotrichosis: a point-source outbreak of sporotrichosis associated with hay bale props in a Halloween haunted house. Arch Int Med. 1997;157:1885-1887.
  6. Kauffman CA. Sporotrichosis. Clin Infect Dis. 1999;29:231-236.
  7. Migaki G, Font RL, Kaplan W, et al. Sporotrichosis in a Pacific white-sided dolphin (Lagenorhynchus obliquidens). Am J Vet Res. 1978;39:1916-1919.
  8. Crothers SL, White SD, Ihrke PJ, et al. Sporotrichosis: a retrospective evaluation of 23 cases seen in northern California (1987-2007). Vet Dermatol. 2009;20:249-259.
  9. Saravanakumar PS, Eslami P, Zar FA. Lymphocutaneous 
sporotrichosis associated with a squirrel bite: case reports and review. Clin Infect Dis. 1996;23:647-648.
  10. Wenker CJ, Kaufman L, Bacciarini LN, et al. Sporotrichosis in a nine-banded armadillo (Dasypus novemcinctus). J Zoo Wildl Med. 1998;29:474-478.
  11. Barros MB, Schubach Ade O, do Valle AC, et al. 
Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis. 2004;38:529-535.
  12. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis. 1995;21:981-985.
  13. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the managements of patients with sporotrichosis. Clin Infect Dis. 2000;30:684-687.
Issue
Cutis - 96(4)
Issue
Cutis - 96(4)
Page Number
218, 227-228
Page Number
218, 227-228
Publications
Publications
Topics
Article Type
Display Headline
What Is Your Diagnosis? Fixed Cutaneous Sporotrichosis
Display Headline
What Is Your Diagnosis? Fixed Cutaneous Sporotrichosis
Legacy Keywords
pediatric dermatology, nodules on the cheek, periocular, midfacial avulsion, Sporothrix schenckii, sporotrichosis, fungal infection, subcutaneous mycosis, environmental dermatology
Legacy Keywords
pediatric dermatology, nodules on the cheek, periocular, midfacial avulsion, Sporothrix schenckii, sporotrichosis, fungal infection, subcutaneous mycosis, environmental dermatology
Sections
Questionnaire Body

A 13-year-old adolescent boy presented with erythematous, tender, scaly, indurated nodules coalescing into plaques on the left cheek and periocular region. He denied any vision changes, the extraocular muscles were intact, and he was afebrile. Two weeks prior to presentation, the patient was hospitalized after an all-terrain vehicle accident that resulted in an extensive midfacial avulsion of the left cheek. The wound was cleaned and repaired by an otorhinolaryngologist. Three days later, he developed swelling and erythema of the left cheek, which was treated by his primary care provider with oral cephalexin, then trimethoprim-sulfamethoxazole for postsurgical wound infection. After completing his antibiotic course, he noticed continued worsening of the wound with increased edema, erythema, and tenderness. He was then referred to our clinic for further evaluation.

Disallow All Ads
Alternative CME
Article PDF Media

Erythematous Scaly Patch on the Jawline

Article Type
Changed
Thu, 01/10/2019 - 13:26
Display Headline
Erythematous Scaly Patch on the Jawline

The Diagnosis: Amelanotic Melanoma In Situ

Histopathology revealed a broad asymmetric melanocytic proliferation at the dermoepidermal junction, consisting both of singly dispersed cells as well as randomly positioned nests (Figure 1). The single cells demonstrated junctional confluence and extension along adnexal structures highlighted by melan-A stain 
(Figure 2). The melanocytes were markedly atypical with enlarged and hyperchromatic nuclei containing multiple nucleoli. No dermal involvement was seen. There was papillary dermal fibrosis and an active host lymphocytic response. Based on these findings, a diagnosis of amelanotic melanoma in situ was made.

  

Figure 1. Histopathology revealed confluence of atypical melanocytes at the dermoepidermal junction and pagetoid scatter of melanocytes to the spinous layer (A)(H&E, original magnification ×4). Higher-power magnification highlighted the atypia of the individual melanocytes (B)(H&E, original magnification ×10).

Figure 2. Melan-A stain highlighted the density and confluence of melanocytes within the epidermis (original magnification ×2).

Subsequent scouting punch biopsies at the superior, anterior, and posterior aspects of the lesion were performed (Figure 3). All 3 revealed a similar nested and single cell proliferation at the dermoepidermal junction, confirming residual amelanotic melanoma in situ. The patient was referred to the otolaryngology department and underwent wide local excision with 5-mm margins and reconstructive repair.

Amelanotic melanoma comprises 2% to 8% of cutaneous melanomas. It is more common in fair-skinned elderly women with an average age of diagnosis of 61.8 years. Because features typically associated with melanoma such as asymmetry, border irregularity, and color variegation often are absent, amelanotic melanoma represents a notable diagnostic challenge for clinicians. Lesions can present nonspecifically as erythematous macules, papules, patches, or plaques and can have associated pruritus and scale.1,2

Figure 3. Three scouting punch biopsies were performed along the periphery of the lesion.

Clinical misdiagnoses for amelanotic melanoma include Bowen disease, basal cell carcinoma, actinic keratosis, lichenoid keratosis, intradermal nevus, dermatofibroma, inflamed seborrheic keratosis, nummular dermatitis, pyogenic granuloma, and granuloma annulare.1-6 There have been few case reports of amelanotic melanoma in situ, with most being the lentigo maligna variant that were initially clinically diagnosed as superficial basal cell carcinoma, 
Bowen disease, or dermatitis.7,8 In one case report, an amelanotic lentigo maligna was incidentally discovered after performing a mapping shave biopsy on what was normal-appearing skin.9

Dermoscopic evidence of vascular structures in lesions, including the presence of dotted vessels, milky red areas, and/or serpentine (linear irregular) vessels, may be the only clues to suggest amelanotic melanoma before biopsy. However, these findings are nonspecific and can be seen in other benign and malignant skin conditions.2

Complete surgical excision is the standard treatment of amelanotic melanoma in situ given its potential for invasion. However, the lack of pigment can make margins difficult to define. Because of its ability to detect disease beyond visual margins, Mohs micrographic surgery may have better cure rates than conventional excision.4 Prognosis for amelanotic melanoma is the same as other melanomas of equal thickness and location, though delay in diagnosis can adversely affect outcomes. Furthermore, amelanotic melanoma in situ can rapidly progress to invasive melanoma.3,5 Thus it is important to maintain clinical suspicion for amelanotic melanoma in fair-skinned elderly women presenting with a persistent or recurring erythematous scaly lesion on sun-exposed skin.

References
  1. Rahbari H, Nabai H, Mehregan AH, et al. Amelanotic lentigo maligna melanoma: a diagnostic conundrum— 
presentation of four new cases. Cancer. 1996;77:2052-2057.
  2. Jaimes N, Braun RP, Thomas L, et al. Clinical and dermoscopic characteristics of amelanotic melanomas that are not of the nodular subtype. J Eur Acad Dermatol Venereol. 2012;26:591-596.
  3. Koch SE, Lange JR. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol. 2000;42:731-734.
  4. Conrad N, Jackson B, Goldberg L. Amelanotic lentigo maligna melanoma: a unique case presentation. Dermatol Surg. 1999;25:408-411.
  5. Cliff S, Otter M, Holden CA. Amelanotic lentigo maligna melanoma of the face: a case report and review of the literature. Clin Exp Dermatol. 1997;22:177-179.
  6. Dalton SR, Fillman EP, Altman CE, et al. Atypical junctional melanocytic proliferations in benign lichenoid keratosis. Hum Pathol. 2003;34:706-709.
  7. Paver K, Stewart M, Kossard S, et al. Amelanotic lentigo maligna. Australas J Dermatol. 1981;22:106-108.
  8. Lewis JE. Lentigo maligna presenting as an eczematous lesion. Cutis. 1987;40:357-359.
  9. Perera E, Mellick N, Teng P, et al. A clinically invisible melanoma. Australas J Dermatol. 2014;55:e58-e59.
Article PDF
Author and Disclosure Information

Dr. Gosis is from Santa Barbara Cottage Hospital, California. Drs. Daniel and Wilson are from the Department of Dermatology, 
University of Virginia, Charlottesville. 


The authors report no conflict of interest.


Correspondence: Julia G. Gosis, MD ([email protected]).

Issue
Cutis - 96(4)
Publications
Topics
Page Number
E4-E6
Legacy Keywords
melanoma, amelanotic, lentigo maligna, basal cell carcinoma, dermatitis
Sections
Author and Disclosure Information

Dr. Gosis is from Santa Barbara Cottage Hospital, California. Drs. Daniel and Wilson are from the Department of Dermatology, 
University of Virginia, Charlottesville. 


The authors report no conflict of interest.


Correspondence: Julia G. Gosis, MD ([email protected]).

Author and Disclosure Information

Dr. Gosis is from Santa Barbara Cottage Hospital, California. Drs. Daniel and Wilson are from the Department of Dermatology, 
University of Virginia, Charlottesville. 


The authors report no conflict of interest.


Correspondence: Julia G. Gosis, MD ([email protected]).

Article PDF
Article PDF

The Diagnosis: Amelanotic Melanoma In Situ

Histopathology revealed a broad asymmetric melanocytic proliferation at the dermoepidermal junction, consisting both of singly dispersed cells as well as randomly positioned nests (Figure 1). The single cells demonstrated junctional confluence and extension along adnexal structures highlighted by melan-A stain 
(Figure 2). The melanocytes were markedly atypical with enlarged and hyperchromatic nuclei containing multiple nucleoli. No dermal involvement was seen. There was papillary dermal fibrosis and an active host lymphocytic response. Based on these findings, a diagnosis of amelanotic melanoma in situ was made.

  

Figure 1. Histopathology revealed confluence of atypical melanocytes at the dermoepidermal junction and pagetoid scatter of melanocytes to the spinous layer (A)(H&E, original magnification ×4). Higher-power magnification highlighted the atypia of the individual melanocytes (B)(H&E, original magnification ×10).

Figure 2. Melan-A stain highlighted the density and confluence of melanocytes within the epidermis (original magnification ×2).

Subsequent scouting punch biopsies at the superior, anterior, and posterior aspects of the lesion were performed (Figure 3). All 3 revealed a similar nested and single cell proliferation at the dermoepidermal junction, confirming residual amelanotic melanoma in situ. The patient was referred to the otolaryngology department and underwent wide local excision with 5-mm margins and reconstructive repair.

Amelanotic melanoma comprises 2% to 8% of cutaneous melanomas. It is more common in fair-skinned elderly women with an average age of diagnosis of 61.8 years. Because features typically associated with melanoma such as asymmetry, border irregularity, and color variegation often are absent, amelanotic melanoma represents a notable diagnostic challenge for clinicians. Lesions can present nonspecifically as erythematous macules, papules, patches, or plaques and can have associated pruritus and scale.1,2

Figure 3. Three scouting punch biopsies were performed along the periphery of the lesion.

Clinical misdiagnoses for amelanotic melanoma include Bowen disease, basal cell carcinoma, actinic keratosis, lichenoid keratosis, intradermal nevus, dermatofibroma, inflamed seborrheic keratosis, nummular dermatitis, pyogenic granuloma, and granuloma annulare.1-6 There have been few case reports of amelanotic melanoma in situ, with most being the lentigo maligna variant that were initially clinically diagnosed as superficial basal cell carcinoma, 
Bowen disease, or dermatitis.7,8 In one case report, an amelanotic lentigo maligna was incidentally discovered after performing a mapping shave biopsy on what was normal-appearing skin.9

Dermoscopic evidence of vascular structures in lesions, including the presence of dotted vessels, milky red areas, and/or serpentine (linear irregular) vessels, may be the only clues to suggest amelanotic melanoma before biopsy. However, these findings are nonspecific and can be seen in other benign and malignant skin conditions.2

Complete surgical excision is the standard treatment of amelanotic melanoma in situ given its potential for invasion. However, the lack of pigment can make margins difficult to define. Because of its ability to detect disease beyond visual margins, Mohs micrographic surgery may have better cure rates than conventional excision.4 Prognosis for amelanotic melanoma is the same as other melanomas of equal thickness and location, though delay in diagnosis can adversely affect outcomes. Furthermore, amelanotic melanoma in situ can rapidly progress to invasive melanoma.3,5 Thus it is important to maintain clinical suspicion for amelanotic melanoma in fair-skinned elderly women presenting with a persistent or recurring erythematous scaly lesion on sun-exposed skin.

The Diagnosis: Amelanotic Melanoma In Situ

Histopathology revealed a broad asymmetric melanocytic proliferation at the dermoepidermal junction, consisting both of singly dispersed cells as well as randomly positioned nests (Figure 1). The single cells demonstrated junctional confluence and extension along adnexal structures highlighted by melan-A stain 
(Figure 2). The melanocytes were markedly atypical with enlarged and hyperchromatic nuclei containing multiple nucleoli. No dermal involvement was seen. There was papillary dermal fibrosis and an active host lymphocytic response. Based on these findings, a diagnosis of amelanotic melanoma in situ was made.

  

Figure 1. Histopathology revealed confluence of atypical melanocytes at the dermoepidermal junction and pagetoid scatter of melanocytes to the spinous layer (A)(H&E, original magnification ×4). Higher-power magnification highlighted the atypia of the individual melanocytes (B)(H&E, original magnification ×10).

Figure 2. Melan-A stain highlighted the density and confluence of melanocytes within the epidermis (original magnification ×2).

Subsequent scouting punch biopsies at the superior, anterior, and posterior aspects of the lesion were performed (Figure 3). All 3 revealed a similar nested and single cell proliferation at the dermoepidermal junction, confirming residual amelanotic melanoma in situ. The patient was referred to the otolaryngology department and underwent wide local excision with 5-mm margins and reconstructive repair.

Amelanotic melanoma comprises 2% to 8% of cutaneous melanomas. It is more common in fair-skinned elderly women with an average age of diagnosis of 61.8 years. Because features typically associated with melanoma such as asymmetry, border irregularity, and color variegation often are absent, amelanotic melanoma represents a notable diagnostic challenge for clinicians. Lesions can present nonspecifically as erythematous macules, papules, patches, or plaques and can have associated pruritus and scale.1,2

Figure 3. Three scouting punch biopsies were performed along the periphery of the lesion.

Clinical misdiagnoses for amelanotic melanoma include Bowen disease, basal cell carcinoma, actinic keratosis, lichenoid keratosis, intradermal nevus, dermatofibroma, inflamed seborrheic keratosis, nummular dermatitis, pyogenic granuloma, and granuloma annulare.1-6 There have been few case reports of amelanotic melanoma in situ, with most being the lentigo maligna variant that were initially clinically diagnosed as superficial basal cell carcinoma, 
Bowen disease, or dermatitis.7,8 In one case report, an amelanotic lentigo maligna was incidentally discovered after performing a mapping shave biopsy on what was normal-appearing skin.9

Dermoscopic evidence of vascular structures in lesions, including the presence of dotted vessels, milky red areas, and/or serpentine (linear irregular) vessels, may be the only clues to suggest amelanotic melanoma before biopsy. However, these findings are nonspecific and can be seen in other benign and malignant skin conditions.2

Complete surgical excision is the standard treatment of amelanotic melanoma in situ given its potential for invasion. However, the lack of pigment can make margins difficult to define. Because of its ability to detect disease beyond visual margins, Mohs micrographic surgery may have better cure rates than conventional excision.4 Prognosis for amelanotic melanoma is the same as other melanomas of equal thickness and location, though delay in diagnosis can adversely affect outcomes. Furthermore, amelanotic melanoma in situ can rapidly progress to invasive melanoma.3,5 Thus it is important to maintain clinical suspicion for amelanotic melanoma in fair-skinned elderly women presenting with a persistent or recurring erythematous scaly lesion on sun-exposed skin.

References
  1. Rahbari H, Nabai H, Mehregan AH, et al. Amelanotic lentigo maligna melanoma: a diagnostic conundrum— 
presentation of four new cases. Cancer. 1996;77:2052-2057.
  2. Jaimes N, Braun RP, Thomas L, et al. Clinical and dermoscopic characteristics of amelanotic melanomas that are not of the nodular subtype. J Eur Acad Dermatol Venereol. 2012;26:591-596.
  3. Koch SE, Lange JR. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol. 2000;42:731-734.
  4. Conrad N, Jackson B, Goldberg L. Amelanotic lentigo maligna melanoma: a unique case presentation. Dermatol Surg. 1999;25:408-411.
  5. Cliff S, Otter M, Holden CA. Amelanotic lentigo maligna melanoma of the face: a case report and review of the literature. Clin Exp Dermatol. 1997;22:177-179.
  6. Dalton SR, Fillman EP, Altman CE, et al. Atypical junctional melanocytic proliferations in benign lichenoid keratosis. Hum Pathol. 2003;34:706-709.
  7. Paver K, Stewart M, Kossard S, et al. Amelanotic lentigo maligna. Australas J Dermatol. 1981;22:106-108.
  8. Lewis JE. Lentigo maligna presenting as an eczematous lesion. Cutis. 1987;40:357-359.
  9. Perera E, Mellick N, Teng P, et al. A clinically invisible melanoma. Australas J Dermatol. 2014;55:e58-e59.
References
  1. Rahbari H, Nabai H, Mehregan AH, et al. Amelanotic lentigo maligna melanoma: a diagnostic conundrum— 
presentation of four new cases. Cancer. 1996;77:2052-2057.
  2. Jaimes N, Braun RP, Thomas L, et al. Clinical and dermoscopic characteristics of amelanotic melanomas that are not of the nodular subtype. J Eur Acad Dermatol Venereol. 2012;26:591-596.
  3. Koch SE, Lange JR. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol. 2000;42:731-734.
  4. Conrad N, Jackson B, Goldberg L. Amelanotic lentigo maligna melanoma: a unique case presentation. Dermatol Surg. 1999;25:408-411.
  5. Cliff S, Otter M, Holden CA. Amelanotic lentigo maligna melanoma of the face: a case report and review of the literature. Clin Exp Dermatol. 1997;22:177-179.
  6. Dalton SR, Fillman EP, Altman CE, et al. Atypical junctional melanocytic proliferations in benign lichenoid keratosis. Hum Pathol. 2003;34:706-709.
  7. Paver K, Stewart M, Kossard S, et al. Amelanotic lentigo maligna. Australas J Dermatol. 1981;22:106-108.
  8. Lewis JE. Lentigo maligna presenting as an eczematous lesion. Cutis. 1987;40:357-359.
  9. Perera E, Mellick N, Teng P, et al. A clinically invisible melanoma. Australas J Dermatol. 2014;55:e58-e59.
Issue
Cutis - 96(4)
Issue
Cutis - 96(4)
Page Number
E4-E6
Page Number
E4-E6
Publications
Publications
Topics
Article Type
Display Headline
Erythematous Scaly Patch on the Jawline
Display Headline
Erythematous Scaly Patch on the Jawline
Legacy Keywords
melanoma, amelanotic, lentigo maligna, basal cell carcinoma, dermatitis
Legacy Keywords
melanoma, amelanotic, lentigo maligna, basal cell carcinoma, dermatitis
Sections
Questionnaire Body

Confluence of atypical melanocytes at the dermoepidermal junction and pagetoid scatter of melanocytes to the spinous layer.
Atypia of the individual melanocytes.
Melan-A stain highlighted the density and confluence of melanocytes within the epidermis.
Three scouting punch biopsies were performed along the periphery of the lesion.

A 70-year-old white woman with a history of basal cell carcinoma presented with a 
2.7×1.9-cm ill-defined, erythematous, scaly patch along the left side of the jawline. 
Ten months prior to presentation, the lesion appeared as a grayish macule that was clinically diagnosed as a pigmented actinic keratosis and was treated with cryotherapy with resolution noted at 6-month follow-up. Differential diagnosis of the current lesion included actinic keratosis, lichenoid keratosis, and superficial basal cell carcinoma. A shave biopsy was performed.

 

Disallow All Ads
Alternative CME
Article PDF Media

Vegetative Sacral Plaque in a Patient With Human Immunodeficiency Virus

Article Type
Changed
Thu, 01/10/2019 - 13:25
Display Headline
Vegetative Sacral Plaque in a Patient With Human Immunodeficiency Virus

The Diagnosis: Herpes Simplex Vegetans

Histopathologic examination using hematoxylin and eosin stain demonstrated marked pseudoepitheliomatous hyperplasia with granulation tissue, ulceration, and abundant exudate joined by a dense mixed inflammatory cell infiltrate that included a myriad of eosinophils (Figure, A). At higher power (Figure, B), many single and multinucleate acantholytic keratinocytes showed ground-glass nuclei and peripheral margination of chromatin within zones of ulceration and crust. Viral culture and direct fluorescent antibody assay identified herpes simplex virus (HSV) type 2. Based on the clinical and histopathologic findings, the patient was diagnosed with herpes simplex vegetans. He was initially treated with oral acyclovir and then oral famciclovir but showed minimal improvement. Eventually, he was referred to surgery and the mass was totally excised with clear margins and no evidence of underlying malignancy.

  
Histopathology revealed marked pseudoepitheliomatous hyperplasia, ulceration, and a dense mixed inflammatory cell infiltrate (A)(H&E, original magnification ×20). Many multinucleate acantholytic keratinocytes with ground-glass nuclei and peripheral margination of chromatin were shown (B)(H&E, original magnification ×400).

Herpes simplex virus is one of the most common sexually transmitted infections, with a notably increased incidence and prevalence among individuals with human immunodeficiency virus (HIV) infection.1 Although typical HSV manifestation in immunocompetent patients includes clustered vesicles and/or ulcerations, immunocompromised patients may have unusual presentations, such as persistent and extensive ulcerations or nodular hyperkeratotic lesions.2,3 Herpes vegetans, a term used to describe these atypical exophytic lesions, rarely has been reported in literature, but its presence should raise suspicion for possible underlying immunocompromise. The pathogenesis behind the hypertrophic nature of these lesions is not well understood, but it is postulated that the immune dysregulation from concomitant HIV and HSV infection plays a role.2 Overproduction of tumor necrosis factor and IL-6 by HIV-infected dermal dendritic cells causes an increase in antiapoptotic factors within the epidermis, resulting in enhanced keratinocyte proliferation and clinical hyperkeratosis.2,4

The differential diagnosis for herpes vegetans is somewhat broad, owing to the verrucous and often eroded appearance of the lesions. Biopsy and cultures can be obtained to differentiate from condyloma acuminatum, condyloma latum (secondary syphilis), pyoderma vegetans, pemphigus vegetans, granuloma inguinale, extraintestinal Crohn disease, deep fungal infections, cutaneous tuberculosis, and malignancy.2-4 Histopathology shows epithelial hyperplasia and ulceration with scattered multinucleate keratinocytes, usually at the periphery of the ulcer, and intranuclear inclusions typical of HSV. In addition, a dense dermal infiltrate of lymphocytes, histiocytes, plasma cells, and eosinophils is usually present beneath the base of the ulcer.2,4

Treatment options for herpes vegetans are limited due to the high prevalence of acyclovir-resistant (ACV-R) HSV-2 strains in HIV patients. Valacyclovir and penciclovir have been largely ineffective against ACV-R HSV due to their dependence on the same enzyme—thymidine kinase—involved in the mechanism of acyclovir resistance. Intravenous foscarnet and cidofovir have shown efficacy against ACV-R virus, but concerns of nephrotoxicity have limited their use over prolonged intervals.5 Castelo-Soccio et al6 reported promising results with intralesional cidofovir. This route of administration provides the advantage of increased bioavailability with reduced risk for nephrotoxicity.6 Finally, surgical resection may be considered for refractory lesions to circumvent the toxicity from systemically administered drugs.3

References
  1. Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol. 1999;135:1393-1397.
  2. Patel AB, Rosen T. Herpes vegetans as a sign of HIV infection. Dermatol Online J. 2008;14:6.
  3. Chung VQ, Parker DC, Parker SR. Surgical excision for vegetative herpes simplex virus infection. Dermatol Surg. 2007;33:1374-1379.
  4. Beasley KL, Cooley GE, Kao GF, et al. Herpes simplex 
vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency. J Am Acad Dermatol. 1997;37(5, pt 2):860-863.
  5. Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin. 2003;21:311-320.
  6. Castelo-Soccio L, Bernardin R, Stern J, et al. Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir. Arch Dermatol. 2010;146:124-126.
Article PDF
Author and Disclosure Information

Dr. Elosiebo is from the Department of Dermatology, Indiana University, Indianapolis. Drs. Koubek, Patel, Randall, and Skinner are from the Department of Dermatology, University of Tennessee Health Sciences Center, Memphis.

The authors report no conflict of interest.

Correspondence: Virginia A. Koubek, MD, 930 Madison Ave, Ste 840, Memphis, TN 38163 ([email protected]).

Issue
Cutis - 96(3)
Publications
Topics
Page Number
E7-E9
Legacy Keywords
herpes simplex virus, human immunodeficiency virus, acyclovir-resistance, herpes vegetans, surgical excision, immunocompromise, vegetative plaque, treatment-resistant herpes simplex
Sections
Author and Disclosure Information

Dr. Elosiebo is from the Department of Dermatology, Indiana University, Indianapolis. Drs. Koubek, Patel, Randall, and Skinner are from the Department of Dermatology, University of Tennessee Health Sciences Center, Memphis.

The authors report no conflict of interest.

Correspondence: Virginia A. Koubek, MD, 930 Madison Ave, Ste 840, Memphis, TN 38163 ([email protected]).

Author and Disclosure Information

Dr. Elosiebo is from the Department of Dermatology, Indiana University, Indianapolis. Drs. Koubek, Patel, Randall, and Skinner are from the Department of Dermatology, University of Tennessee Health Sciences Center, Memphis.

The authors report no conflict of interest.

Correspondence: Virginia A. Koubek, MD, 930 Madison Ave, Ste 840, Memphis, TN 38163 ([email protected]).

Article PDF
Article PDF

The Diagnosis: Herpes Simplex Vegetans

Histopathologic examination using hematoxylin and eosin stain demonstrated marked pseudoepitheliomatous hyperplasia with granulation tissue, ulceration, and abundant exudate joined by a dense mixed inflammatory cell infiltrate that included a myriad of eosinophils (Figure, A). At higher power (Figure, B), many single and multinucleate acantholytic keratinocytes showed ground-glass nuclei and peripheral margination of chromatin within zones of ulceration and crust. Viral culture and direct fluorescent antibody assay identified herpes simplex virus (HSV) type 2. Based on the clinical and histopathologic findings, the patient was diagnosed with herpes simplex vegetans. He was initially treated with oral acyclovir and then oral famciclovir but showed minimal improvement. Eventually, he was referred to surgery and the mass was totally excised with clear margins and no evidence of underlying malignancy.

  
Histopathology revealed marked pseudoepitheliomatous hyperplasia, ulceration, and a dense mixed inflammatory cell infiltrate (A)(H&E, original magnification ×20). Many multinucleate acantholytic keratinocytes with ground-glass nuclei and peripheral margination of chromatin were shown (B)(H&E, original magnification ×400).

Herpes simplex virus is one of the most common sexually transmitted infections, with a notably increased incidence and prevalence among individuals with human immunodeficiency virus (HIV) infection.1 Although typical HSV manifestation in immunocompetent patients includes clustered vesicles and/or ulcerations, immunocompromised patients may have unusual presentations, such as persistent and extensive ulcerations or nodular hyperkeratotic lesions.2,3 Herpes vegetans, a term used to describe these atypical exophytic lesions, rarely has been reported in literature, but its presence should raise suspicion for possible underlying immunocompromise. The pathogenesis behind the hypertrophic nature of these lesions is not well understood, but it is postulated that the immune dysregulation from concomitant HIV and HSV infection plays a role.2 Overproduction of tumor necrosis factor and IL-6 by HIV-infected dermal dendritic cells causes an increase in antiapoptotic factors within the epidermis, resulting in enhanced keratinocyte proliferation and clinical hyperkeratosis.2,4

The differential diagnosis for herpes vegetans is somewhat broad, owing to the verrucous and often eroded appearance of the lesions. Biopsy and cultures can be obtained to differentiate from condyloma acuminatum, condyloma latum (secondary syphilis), pyoderma vegetans, pemphigus vegetans, granuloma inguinale, extraintestinal Crohn disease, deep fungal infections, cutaneous tuberculosis, and malignancy.2-4 Histopathology shows epithelial hyperplasia and ulceration with scattered multinucleate keratinocytes, usually at the periphery of the ulcer, and intranuclear inclusions typical of HSV. In addition, a dense dermal infiltrate of lymphocytes, histiocytes, plasma cells, and eosinophils is usually present beneath the base of the ulcer.2,4

Treatment options for herpes vegetans are limited due to the high prevalence of acyclovir-resistant (ACV-R) HSV-2 strains in HIV patients. Valacyclovir and penciclovir have been largely ineffective against ACV-R HSV due to their dependence on the same enzyme—thymidine kinase—involved in the mechanism of acyclovir resistance. Intravenous foscarnet and cidofovir have shown efficacy against ACV-R virus, but concerns of nephrotoxicity have limited their use over prolonged intervals.5 Castelo-Soccio et al6 reported promising results with intralesional cidofovir. This route of administration provides the advantage of increased bioavailability with reduced risk for nephrotoxicity.6 Finally, surgical resection may be considered for refractory lesions to circumvent the toxicity from systemically administered drugs.3

The Diagnosis: Herpes Simplex Vegetans

Histopathologic examination using hematoxylin and eosin stain demonstrated marked pseudoepitheliomatous hyperplasia with granulation tissue, ulceration, and abundant exudate joined by a dense mixed inflammatory cell infiltrate that included a myriad of eosinophils (Figure, A). At higher power (Figure, B), many single and multinucleate acantholytic keratinocytes showed ground-glass nuclei and peripheral margination of chromatin within zones of ulceration and crust. Viral culture and direct fluorescent antibody assay identified herpes simplex virus (HSV) type 2. Based on the clinical and histopathologic findings, the patient was diagnosed with herpes simplex vegetans. He was initially treated with oral acyclovir and then oral famciclovir but showed minimal improvement. Eventually, he was referred to surgery and the mass was totally excised with clear margins and no evidence of underlying malignancy.

  
Histopathology revealed marked pseudoepitheliomatous hyperplasia, ulceration, and a dense mixed inflammatory cell infiltrate (A)(H&E, original magnification ×20). Many multinucleate acantholytic keratinocytes with ground-glass nuclei and peripheral margination of chromatin were shown (B)(H&E, original magnification ×400).

Herpes simplex virus is one of the most common sexually transmitted infections, with a notably increased incidence and prevalence among individuals with human immunodeficiency virus (HIV) infection.1 Although typical HSV manifestation in immunocompetent patients includes clustered vesicles and/or ulcerations, immunocompromised patients may have unusual presentations, such as persistent and extensive ulcerations or nodular hyperkeratotic lesions.2,3 Herpes vegetans, a term used to describe these atypical exophytic lesions, rarely has been reported in literature, but its presence should raise suspicion for possible underlying immunocompromise. The pathogenesis behind the hypertrophic nature of these lesions is not well understood, but it is postulated that the immune dysregulation from concomitant HIV and HSV infection plays a role.2 Overproduction of tumor necrosis factor and IL-6 by HIV-infected dermal dendritic cells causes an increase in antiapoptotic factors within the epidermis, resulting in enhanced keratinocyte proliferation and clinical hyperkeratosis.2,4

The differential diagnosis for herpes vegetans is somewhat broad, owing to the verrucous and often eroded appearance of the lesions. Biopsy and cultures can be obtained to differentiate from condyloma acuminatum, condyloma latum (secondary syphilis), pyoderma vegetans, pemphigus vegetans, granuloma inguinale, extraintestinal Crohn disease, deep fungal infections, cutaneous tuberculosis, and malignancy.2-4 Histopathology shows epithelial hyperplasia and ulceration with scattered multinucleate keratinocytes, usually at the periphery of the ulcer, and intranuclear inclusions typical of HSV. In addition, a dense dermal infiltrate of lymphocytes, histiocytes, plasma cells, and eosinophils is usually present beneath the base of the ulcer.2,4

Treatment options for herpes vegetans are limited due to the high prevalence of acyclovir-resistant (ACV-R) HSV-2 strains in HIV patients. Valacyclovir and penciclovir have been largely ineffective against ACV-R HSV due to their dependence on the same enzyme—thymidine kinase—involved in the mechanism of acyclovir resistance. Intravenous foscarnet and cidofovir have shown efficacy against ACV-R virus, but concerns of nephrotoxicity have limited their use over prolonged intervals.5 Castelo-Soccio et al6 reported promising results with intralesional cidofovir. This route of administration provides the advantage of increased bioavailability with reduced risk for nephrotoxicity.6 Finally, surgical resection may be considered for refractory lesions to circumvent the toxicity from systemically administered drugs.3

References
  1. Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol. 1999;135:1393-1397.
  2. Patel AB, Rosen T. Herpes vegetans as a sign of HIV infection. Dermatol Online J. 2008;14:6.
  3. Chung VQ, Parker DC, Parker SR. Surgical excision for vegetative herpes simplex virus infection. Dermatol Surg. 2007;33:1374-1379.
  4. Beasley KL, Cooley GE, Kao GF, et al. Herpes simplex 
vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency. J Am Acad Dermatol. 1997;37(5, pt 2):860-863.
  5. Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin. 2003;21:311-320.
  6. Castelo-Soccio L, Bernardin R, Stern J, et al. Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir. Arch Dermatol. 2010;146:124-126.
References
  1. Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol. 1999;135:1393-1397.
  2. Patel AB, Rosen T. Herpes vegetans as a sign of HIV infection. Dermatol Online J. 2008;14:6.
  3. Chung VQ, Parker DC, Parker SR. Surgical excision for vegetative herpes simplex virus infection. Dermatol Surg. 2007;33:1374-1379.
  4. Beasley KL, Cooley GE, Kao GF, et al. Herpes simplex 
vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency. J Am Acad Dermatol. 1997;37(5, pt 2):860-863.
  5. Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin. 2003;21:311-320.
  6. Castelo-Soccio L, Bernardin R, Stern J, et al. Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir. Arch Dermatol. 2010;146:124-126.
Issue
Cutis - 96(3)
Issue
Cutis - 96(3)
Page Number
E7-E9
Page Number
E7-E9
Publications
Publications
Topics
Article Type
Display Headline
Vegetative Sacral Plaque in a Patient With Human Immunodeficiency Virus
Display Headline
Vegetative Sacral Plaque in a Patient With Human Immunodeficiency Virus
Legacy Keywords
herpes simplex virus, human immunodeficiency virus, acyclovir-resistance, herpes vegetans, surgical excision, immunocompromise, vegetative plaque, treatment-resistant herpes simplex
Legacy Keywords
herpes simplex virus, human immunodeficiency virus, acyclovir-resistance, herpes vegetans, surgical excision, immunocompromise, vegetative plaque, treatment-resistant herpes simplex
Sections
Questionnaire Body

A 53-year-old man presented to our clinic with a sacral mass that had progressively enlarged over 2 years. The patient reported occasional oozing from the mass as well as pain when laying flat but denied fever or other symptoms. His medical history was remarkable for human immunodeficiency virus infection with variable adherence to a highly active antiretroviral therapy regimen. At the time of presentation, the patient had a CD4 lymphocyte count of 78 cells/mm3 (reference range, 500–1400 cells/mm3) and a viral load of 290 copies/mL (reference range, 0 copies/mL). Physical examination revealed a 10-cm discrete, moist and pink, exophytic plaque on the sacrum with superficial erosions. The plaque was nontender and without associated lymphadenopathy. The skin and mucous membranes were otherwise clear. A cutaneous biopsy specimen was obtained from the tumor and sent for histopathologic analysis.

 

Disallow All Ads
Alternative CME
Article PDF Media

What Is Your Diagnosis? Idiopathic Guttate Hypomelanosis

Article Type
Changed
Thu, 01/10/2019 - 13:25
Display Headline
What Is Your Diagnosis? Idiopathic Guttate Hypomelanosis

The Diagnosis: Idiopathic Guttate Hypomelanosis

A biopsy of the largest lesion from the left leg 
superior to the lateral malleolus was performed. 
 Histopathologic examination revealed solar elastosis, diminished number of focal melanocytes and pigment within keratinocytes compared to uninvolved skin, and presence of hyperkeratosis with flattening of rete ridges. The clinical presentation along with histopathologic analysis confirmed a diagnosis of idiopathic guttate hypomelanosis (IGH). The lesions were treated with short-exposure cryotherapy, which resulted in partial repigmentation after several treatments.

Idiopathic guttate hypomelanosis is a common but underreported condition in elderly patients that usually presents with small, discrete, asymptomatic, hypopigmented macules. The frequency of IGH increases with age.1 Frequency of the condition is much lower in patients aged 21 to 30 years and does not exceed 7%. Lesions of IGH have a predilection for sun-exposed areas such as the arms and legs but rarely can be seen on the face and trunk. Facial lesions of IGH are more frequently reported in women.1 The size of lesions can be up to 1.5 cm in diameter. The condition generally is self-limited, but some patients may express aesthetic concerns. Rare cases of IGH in children have been associated with prolonged sun exposure.2

The etiology of IGH is unknown but an association with sun exposure has been noted. Patients with IGH frequently show other signs of photoaging, such as numerous seborrheic keratoses, solar lentigines, xeroses, freckles, and actinic keratoses.1 Short-term exposure to UVB radiation and psoralen plus UVA therapy has been shown to cause IGH in patients with chronic diseases such as mycosis fungoides.3-5 One small study that examined renal transplant recipients determined an association between HLA-DQ3 antigens and IGH, whereas HLA-DR8 antigens were not identified in any patients with IGH, indicating it may have some advantage in preventing the development of IGH.6 Shin et al1 reported that IGH was prevalent among patients who regularly traumatized their skin by scrubbing.

Clinically, IGH should be differentiated from other conditions characterized by hypopigmentation, such as pityriasis alba, pityriasis versicolor, postinflammatory hypopigmentation, progressive macular hypomelanosis, and vitiligo. Aside from clinical examination, histopathologic studies are helpful in making a definitive diagnosis. The differential diagnosis of IGH is presented in the Table.

Histopathology of IGH lesions usually reveals slight atrophy of the epidermis with flattening of rete ridges and concomitant hyperkeratosis. A thickened stratum granulosum also has been noted in lesions of IGH.2 The diminished number of melanocytes and melanin pigment granules along with hyperkeratosis both appear to contribute to the hypopigmentation noted in IGH.7 Ultrastructural studies of lesions of IGH can confirm melanocytic degeneration and a decreased number of melanosomes in melanocytes and keratinocytes.2,8

There is no uniformly effective treatment of IGH. Topical application of tacrolimus and tretinoin have shown efficacy in repigmenting IGH lesions.8,9 Short-exposure cryotherapy with a duration of 3 to 
5 seconds, localized chemical peels, and/or local dermabrasion can be helpful.10-12 CO2 lasers also have demonstrated promising results.13

References
  1. Shin MK, Jeong KH, Oh IH, et al. Clinical features of idiopathic guttate hypomelanosis in 646 subjects and association with other aspects of photoaging. Int J Dermatol. 2011;50:798-805.
  2. Kim SK, Kim EH, Kang HY, et al. Comprehensive understanding of idiopathic guttate hypomelanosis: clinical 
and histopathological correlation. Int J Dermatol. 2010;49:162-166.
  3. Friedland R, David M, Feinmesser M, et al. Idiopathic guttate hypomelanosis-like lesions in patients with mycosis fungoides: a new adverse effect of phototherapy. 
J Eur Acad Dermatol Venereol. 2010;24:1026-1030.
  4. Kaya TI, Yazici AC, Tursen U, et al. Idiopathic guttate hypomelanosis: idiopathic or ultraviolet induced? 
Photodermatol Photoimmunol Photomed. 2005;21:270-271.
  5. Loquai C, Metze D, Nashan D, et al. Confetti-like lesions with hyperkeratosis: a novel ultraviolet-induced hypomelanotic disorder? Br J Dermatol. 2005;153:190-193.
  6. Arrunategui A, Trujillo RA, Marulanda MP, et al. 
HLA-DQ3 is associated with idiopathic guttate 
hypomelanosis, whereas HLA-DR8 is not, in a group 
of renal transplant patients. Int J Dermatol. 
2002;41:744-747.
  7. Wallace ML, Grichnik JM, Prieto VG, et al. Numbers and differentiation status of melanocytes in idiopathic guttate hypomelanosis. J Cutan Pathol. 1998;25:375-379.
  8. Ortonne JP, Perrot H. Idiopathic guttate hypomelanosis. ultrastructural study. Arch Dermatol. 1980;116:664-668.
  9. Rerknimitr P, Disphanurat W, Achariyakul M. 
Topical tacrolimus significantly promotes repigmentation in idiopathic guttate hypomelanosis: a double-blind, randomized, placebo-controlled study. J Eur Acad Dermatol Venereol. 2013;27:460-464.
  10. Pagnoni A, Kligman AM, Sadiq I, et al. Hypopigmented macules of photodamaged skin and their treatment with topical tretinoin. Acta Derm Venereol. 1999;79:305-310.
  11. Kumarasinghe SP. 3-5 second cryotherapy is effective 
in idiopathic guttate hypomelanosis. J Dermatol. 2004;31:457-459.
  12. Hexsel DM. Treatment of idiopathic guttate hypomelanosis by localized superficial dermabrasion. Dermatol Surg. 1999;25:917-918.
  13. Shin J, Kim M, Park SH, et al. The effect of fractional carbon dioxide lasers on idiopathic guttate hypomelanosis: a preliminary study. J Eur Acad Dermatol Venereol. 2013;27:e243-e246.
Article PDF
Author and Disclosure Information

Mr. Lal is from New York Institute of Technology College of Osteopathic Medicine, Old Westbury. Dr. Kazlouskaya is from and Dr. Elston 
was from the Ackerman Academy of Dermatopathology, New York, New York. Dr. Elston currently is from the Department of Dermatology, Medical University of South Carolina, Charleston.

The authors report no conflict of interest.

Correspondence: Karan Lal, BS, PO Box 8000, Northern Blvd, Old Westbury, NY 11568 ([email protected]).

Issue
Cutis - 96(3)
Publications
Topics
Page Number
156, 184-185
Legacy Keywords
Idiopathic guttatae hypomelanosis, melanocytes, cryotherapy, hypopigmented lesions, IGH, hypopigmentation
Sections
Author and Disclosure Information

Mr. Lal is from New York Institute of Technology College of Osteopathic Medicine, Old Westbury. Dr. Kazlouskaya is from and Dr. Elston 
was from the Ackerman Academy of Dermatopathology, New York, New York. Dr. Elston currently is from the Department of Dermatology, Medical University of South Carolina, Charleston.

The authors report no conflict of interest.

Correspondence: Karan Lal, BS, PO Box 8000, Northern Blvd, Old Westbury, NY 11568 ([email protected]).

Author and Disclosure Information

Mr. Lal is from New York Institute of Technology College of Osteopathic Medicine, Old Westbury. Dr. Kazlouskaya is from and Dr. Elston 
was from the Ackerman Academy of Dermatopathology, New York, New York. Dr. Elston currently is from the Department of Dermatology, Medical University of South Carolina, Charleston.

The authors report no conflict of interest.

Correspondence: Karan Lal, BS, PO Box 8000, Northern Blvd, Old Westbury, NY 11568 ([email protected]).

Article PDF
Article PDF
Related Articles

The Diagnosis: Idiopathic Guttate Hypomelanosis

A biopsy of the largest lesion from the left leg 
superior to the lateral malleolus was performed. 
 Histopathologic examination revealed solar elastosis, diminished number of focal melanocytes and pigment within keratinocytes compared to uninvolved skin, and presence of hyperkeratosis with flattening of rete ridges. The clinical presentation along with histopathologic analysis confirmed a diagnosis of idiopathic guttate hypomelanosis (IGH). The lesions were treated with short-exposure cryotherapy, which resulted in partial repigmentation after several treatments.

Idiopathic guttate hypomelanosis is a common but underreported condition in elderly patients that usually presents with small, discrete, asymptomatic, hypopigmented macules. The frequency of IGH increases with age.1 Frequency of the condition is much lower in patients aged 21 to 30 years and does not exceed 7%. Lesions of IGH have a predilection for sun-exposed areas such as the arms and legs but rarely can be seen on the face and trunk. Facial lesions of IGH are more frequently reported in women.1 The size of lesions can be up to 1.5 cm in diameter. The condition generally is self-limited, but some patients may express aesthetic concerns. Rare cases of IGH in children have been associated with prolonged sun exposure.2

The etiology of IGH is unknown but an association with sun exposure has been noted. Patients with IGH frequently show other signs of photoaging, such as numerous seborrheic keratoses, solar lentigines, xeroses, freckles, and actinic keratoses.1 Short-term exposure to UVB radiation and psoralen plus UVA therapy has been shown to cause IGH in patients with chronic diseases such as mycosis fungoides.3-5 One small study that examined renal transplant recipients determined an association between HLA-DQ3 antigens and IGH, whereas HLA-DR8 antigens were not identified in any patients with IGH, indicating it may have some advantage in preventing the development of IGH.6 Shin et al1 reported that IGH was prevalent among patients who regularly traumatized their skin by scrubbing.

Clinically, IGH should be differentiated from other conditions characterized by hypopigmentation, such as pityriasis alba, pityriasis versicolor, postinflammatory hypopigmentation, progressive macular hypomelanosis, and vitiligo. Aside from clinical examination, histopathologic studies are helpful in making a definitive diagnosis. The differential diagnosis of IGH is presented in the Table.

Histopathology of IGH lesions usually reveals slight atrophy of the epidermis with flattening of rete ridges and concomitant hyperkeratosis. A thickened stratum granulosum also has been noted in lesions of IGH.2 The diminished number of melanocytes and melanin pigment granules along with hyperkeratosis both appear to contribute to the hypopigmentation noted in IGH.7 Ultrastructural studies of lesions of IGH can confirm melanocytic degeneration and a decreased number of melanosomes in melanocytes and keratinocytes.2,8

There is no uniformly effective treatment of IGH. Topical application of tacrolimus and tretinoin have shown efficacy in repigmenting IGH lesions.8,9 Short-exposure cryotherapy with a duration of 3 to 
5 seconds, localized chemical peels, and/or local dermabrasion can be helpful.10-12 CO2 lasers also have demonstrated promising results.13

The Diagnosis: Idiopathic Guttate Hypomelanosis

A biopsy of the largest lesion from the left leg 
superior to the lateral malleolus was performed. 
 Histopathologic examination revealed solar elastosis, diminished number of focal melanocytes and pigment within keratinocytes compared to uninvolved skin, and presence of hyperkeratosis with flattening of rete ridges. The clinical presentation along with histopathologic analysis confirmed a diagnosis of idiopathic guttate hypomelanosis (IGH). The lesions were treated with short-exposure cryotherapy, which resulted in partial repigmentation after several treatments.

Idiopathic guttate hypomelanosis is a common but underreported condition in elderly patients that usually presents with small, discrete, asymptomatic, hypopigmented macules. The frequency of IGH increases with age.1 Frequency of the condition is much lower in patients aged 21 to 30 years and does not exceed 7%. Lesions of IGH have a predilection for sun-exposed areas such as the arms and legs but rarely can be seen on the face and trunk. Facial lesions of IGH are more frequently reported in women.1 The size of lesions can be up to 1.5 cm in diameter. The condition generally is self-limited, but some patients may express aesthetic concerns. Rare cases of IGH in children have been associated with prolonged sun exposure.2

The etiology of IGH is unknown but an association with sun exposure has been noted. Patients with IGH frequently show other signs of photoaging, such as numerous seborrheic keratoses, solar lentigines, xeroses, freckles, and actinic keratoses.1 Short-term exposure to UVB radiation and psoralen plus UVA therapy has been shown to cause IGH in patients with chronic diseases such as mycosis fungoides.3-5 One small study that examined renal transplant recipients determined an association between HLA-DQ3 antigens and IGH, whereas HLA-DR8 antigens were not identified in any patients with IGH, indicating it may have some advantage in preventing the development of IGH.6 Shin et al1 reported that IGH was prevalent among patients who regularly traumatized their skin by scrubbing.

Clinically, IGH should be differentiated from other conditions characterized by hypopigmentation, such as pityriasis alba, pityriasis versicolor, postinflammatory hypopigmentation, progressive macular hypomelanosis, and vitiligo. Aside from clinical examination, histopathologic studies are helpful in making a definitive diagnosis. The differential diagnosis of IGH is presented in the Table.

Histopathology of IGH lesions usually reveals slight atrophy of the epidermis with flattening of rete ridges and concomitant hyperkeratosis. A thickened stratum granulosum also has been noted in lesions of IGH.2 The diminished number of melanocytes and melanin pigment granules along with hyperkeratosis both appear to contribute to the hypopigmentation noted in IGH.7 Ultrastructural studies of lesions of IGH can confirm melanocytic degeneration and a decreased number of melanosomes in melanocytes and keratinocytes.2,8

There is no uniformly effective treatment of IGH. Topical application of tacrolimus and tretinoin have shown efficacy in repigmenting IGH lesions.8,9 Short-exposure cryotherapy with a duration of 3 to 
5 seconds, localized chemical peels, and/or local dermabrasion can be helpful.10-12 CO2 lasers also have demonstrated promising results.13

References
  1. Shin MK, Jeong KH, Oh IH, et al. Clinical features of idiopathic guttate hypomelanosis in 646 subjects and association with other aspects of photoaging. Int J Dermatol. 2011;50:798-805.
  2. Kim SK, Kim EH, Kang HY, et al. Comprehensive understanding of idiopathic guttate hypomelanosis: clinical 
and histopathological correlation. Int J Dermatol. 2010;49:162-166.
  3. Friedland R, David M, Feinmesser M, et al. Idiopathic guttate hypomelanosis-like lesions in patients with mycosis fungoides: a new adverse effect of phototherapy. 
J Eur Acad Dermatol Venereol. 2010;24:1026-1030.
  4. Kaya TI, Yazici AC, Tursen U, et al. Idiopathic guttate hypomelanosis: idiopathic or ultraviolet induced? 
Photodermatol Photoimmunol Photomed. 2005;21:270-271.
  5. Loquai C, Metze D, Nashan D, et al. Confetti-like lesions with hyperkeratosis: a novel ultraviolet-induced hypomelanotic disorder? Br J Dermatol. 2005;153:190-193.
  6. Arrunategui A, Trujillo RA, Marulanda MP, et al. 
HLA-DQ3 is associated with idiopathic guttate 
hypomelanosis, whereas HLA-DR8 is not, in a group 
of renal transplant patients. Int J Dermatol. 
2002;41:744-747.
  7. Wallace ML, Grichnik JM, Prieto VG, et al. Numbers and differentiation status of melanocytes in idiopathic guttate hypomelanosis. J Cutan Pathol. 1998;25:375-379.
  8. Ortonne JP, Perrot H. Idiopathic guttate hypomelanosis. ultrastructural study. Arch Dermatol. 1980;116:664-668.
  9. Rerknimitr P, Disphanurat W, Achariyakul M. 
Topical tacrolimus significantly promotes repigmentation in idiopathic guttate hypomelanosis: a double-blind, randomized, placebo-controlled study. J Eur Acad Dermatol Venereol. 2013;27:460-464.
  10. Pagnoni A, Kligman AM, Sadiq I, et al. Hypopigmented macules of photodamaged skin and their treatment with topical tretinoin. Acta Derm Venereol. 1999;79:305-310.
  11. Kumarasinghe SP. 3-5 second cryotherapy is effective 
in idiopathic guttate hypomelanosis. J Dermatol. 2004;31:457-459.
  12. Hexsel DM. Treatment of idiopathic guttate hypomelanosis by localized superficial dermabrasion. Dermatol Surg. 1999;25:917-918.
  13. Shin J, Kim M, Park SH, et al. The effect of fractional carbon dioxide lasers on idiopathic guttate hypomelanosis: a preliminary study. J Eur Acad Dermatol Venereol. 2013;27:e243-e246.
References
  1. Shin MK, Jeong KH, Oh IH, et al. Clinical features of idiopathic guttate hypomelanosis in 646 subjects and association with other aspects of photoaging. Int J Dermatol. 2011;50:798-805.
  2. Kim SK, Kim EH, Kang HY, et al. Comprehensive understanding of idiopathic guttate hypomelanosis: clinical 
and histopathological correlation. Int J Dermatol. 2010;49:162-166.
  3. Friedland R, David M, Feinmesser M, et al. Idiopathic guttate hypomelanosis-like lesions in patients with mycosis fungoides: a new adverse effect of phototherapy. 
J Eur Acad Dermatol Venereol. 2010;24:1026-1030.
  4. Kaya TI, Yazici AC, Tursen U, et al. Idiopathic guttate hypomelanosis: idiopathic or ultraviolet induced? 
Photodermatol Photoimmunol Photomed. 2005;21:270-271.
  5. Loquai C, Metze D, Nashan D, et al. Confetti-like lesions with hyperkeratosis: a novel ultraviolet-induced hypomelanotic disorder? Br J Dermatol. 2005;153:190-193.
  6. Arrunategui A, Trujillo RA, Marulanda MP, et al. 
HLA-DQ3 is associated with idiopathic guttate 
hypomelanosis, whereas HLA-DR8 is not, in a group 
of renal transplant patients. Int J Dermatol. 
2002;41:744-747.
  7. Wallace ML, Grichnik JM, Prieto VG, et al. Numbers and differentiation status of melanocytes in idiopathic guttate hypomelanosis. J Cutan Pathol. 1998;25:375-379.
  8. Ortonne JP, Perrot H. Idiopathic guttate hypomelanosis. ultrastructural study. Arch Dermatol. 1980;116:664-668.
  9. Rerknimitr P, Disphanurat W, Achariyakul M. 
Topical tacrolimus significantly promotes repigmentation in idiopathic guttate hypomelanosis: a double-blind, randomized, placebo-controlled study. J Eur Acad Dermatol Venereol. 2013;27:460-464.
  10. Pagnoni A, Kligman AM, Sadiq I, et al. Hypopigmented macules of photodamaged skin and their treatment with topical tretinoin. Acta Derm Venereol. 1999;79:305-310.
  11. Kumarasinghe SP. 3-5 second cryotherapy is effective 
in idiopathic guttate hypomelanosis. J Dermatol. 2004;31:457-459.
  12. Hexsel DM. Treatment of idiopathic guttate hypomelanosis by localized superficial dermabrasion. Dermatol Surg. 1999;25:917-918.
  13. Shin J, Kim M, Park SH, et al. The effect of fractional carbon dioxide lasers on idiopathic guttate hypomelanosis: a preliminary study. J Eur Acad Dermatol Venereol. 2013;27:e243-e246.
Issue
Cutis - 96(3)
Issue
Cutis - 96(3)
Page Number
156, 184-185
Page Number
156, 184-185
Publications
Publications
Topics
Article Type
Display Headline
What Is Your Diagnosis? Idiopathic Guttate Hypomelanosis
Display Headline
What Is Your Diagnosis? Idiopathic Guttate Hypomelanosis
Legacy Keywords
Idiopathic guttatae hypomelanosis, melanocytes, cryotherapy, hypopigmented lesions, IGH, hypopigmentation
Legacy Keywords
Idiopathic guttatae hypomelanosis, melanocytes, cryotherapy, hypopigmented lesions, IGH, hypopigmentation
Sections
Questionnaire Body

A 58-year-old man presented with disseminated, hypopigmented, asymptomatic lesions on the right arm (top) and left leg (bottom) that had been present for approximately 6 years. The patient reported that the lesions had become more visible and greater in number within the last year. 
Multiple circular hypopigmented macules of various sizes ranging from 1 to 3 mm in diameter were identified. No scaling was seen. Physical examination was otherwise unremarkable.

Disallow All Ads
Alternative CME
Article PDF Media

Painful Skin Lesions on the Hands Following Black Henna Application

Article Type
Changed
Thu, 01/10/2019 - 13:25
Display Headline
Painful Skin Lesions on the Hands Following Black Henna Application

The Diagnosis: Allergic Contact Dermatitis to 
Para-phenylenediamine

To darken the color of henna and increase penetrance and staining, para-phenylenediamine (PPD) is added.1 Allergic contact dermatitis is the most common type of hypersensitivity to PPD.2 A retrospective study that examined severe adverse events from applying henna dyes in children found that angioedema of mucosal tissues was the most common severe adverse event; others included renal failure and shock.3

Black henna is associated with multiple cultural practices. For example, Indian weddings contain a henna decoration ceremony for the bride based on the belief that the longer the henna lasts, the longer the marriage lasts. Black henna is favored for this practice, as it lasts longer than red henna.

 

Red henna tattoo on the palmar surfaces of the hands.

Henna (Lawsonia inermis) is a plant that contains the molecule lawsone (naphthoquinone). Lawsone has an intense affinity for keratin; as a result, lawsone is frequently added to temporary body tattoos and hair dyes to create a relatively permanent change in skin or hair color.4 Henna is mixed with hennotannic acid to release the lawsone from the plant. Lawsone and hennotannic acid rarely cause allergic reactions.1,5-7 Once applied to skin, henna takes a few hours to dry, and the resulting color is orange to red.8 Often, PPD is added to henna paste to create a black color, to speed up the drying process, and to increase its longevity.

Para-phenylenediamine has been repeatedly reported to cause allergic contact dermatitis. We describe a case of allergic contact dermatitis secondary to PPD in black henna. Our patient is a clear example that PPD is the allergen in black henna given that there was no reaction to the natural red henna tattoo that was applied at the same time to the palmar surfaces of the hands (Figure). Aside from the bullous reaction to black henna dye described here, other reported presentations include erythema multiforme–like and exudative erythema reactions.9,10

Contact dermatitis lesions from black henna dye can be treated with topical corticosteroids. Patients may develop residual postinflammatory hyperpigmentation or hypopigmentation, leukoderma, keloids, or scars.1,11,12

References
  1. Onder M, Atahan CA, Oztas P, et al. Temporary henna tattoo reactions in children. Int J Dermatol. 2001;40:577-579.
  2. Marcoux D, Couture-Trudel PM, Rboulet-Delmas G, 
et al. Sensitization to paraphenylenediame from a streetside temporary tattoo. Pediatr Dermatol. 2002;19:498-502.
  3. Hashim S, Hamza Y, Yahia B, et al. Poisoning from henna dye and para-phenylenediamine mixtures in children in Khartoum. Ann Trop Paediatr. 1992;12:3-6.
  4. Hijji Y, Barare B, Zhang Y. Lawsone (2- hydroxy-1, 
4-naphthoquinone) as a sensitive cyanide and acetate sensor. Sensors and Actuators B: Chemical. 2012;169:106-112.
  5. Neri I, Guareschi E, Savoia F, et al. Childhood allergic contact dermatitis from henna tattoo. Pediatr Dermatol. 2002;19:503-505.
  6. Evans CC, Fleming JD. Allergic contact dermatitis from a henna tattoo. N Engl J Med. 2008;359:627.
  7. Belhadjali H, Akkari H, Youssef M, et al. Bullous allergic contact dermatitis to pure henna in a 3-year-old girl. 
Pediatr Dermatol. 2011;28:580-581.
  8. Najem N, Bagher Zadeh V. Allergic contact dermatitis to black henna. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20:87-88.
  9. Sidwell RU, Francis ND, Basarab T, et al. Vesicular erythema multiforme-like reaction to para-phenylenediamine in a henna tattoo. Pediatr Dermatol. 2008;25:201-204.
  10. Jovanovic DL, Slavkovic-Jovanovic MR. Allergic contact dermatitis from temporary henna tattoo. J Dermatol. 2009;36:63-65.
  11. Valsecchi R, Leghissa P, Di Landro A, et al. 
Persistent leukoderma after henna tattoo. Contact 
Dermatitis. 2007;56:108-109.
  12. Gunasti S, Aksungur VL. Severe inflammatory and keloidal, allergic reaction due to para-phenylenediamine in temporary tattoos. Indian J Dermatol Venereol Leprol. 2010;76:165-167.
Article PDF
Author and Disclosure Information

Dr. Guo is from the Department of Internal Medicine, Brown University, Providence, Rhode Island. Dr. Sato is from Sato Dermatology, Honolulu, Hawaii. Dr. Rothman is from the Department of Pediatric Dermatology, Women & Children’s Hospital of Buffalo, New York.

The authors report no conflict of interest.

Correspondence: Canting Guo, MD, Rhode Island Hospital, Jane Brown Building, 593 Eddy St, Providence, RI 02903 ([email protected]).
 

Issue
Cutis - 96(3)
Publications
Topics
Page Number
E5-E6
Legacy Keywords
black henna, para-phenylenediamine, allergic contact dermatitis
Sections
Author and Disclosure Information

Dr. Guo is from the Department of Internal Medicine, Brown University, Providence, Rhode Island. Dr. Sato is from Sato Dermatology, Honolulu, Hawaii. Dr. Rothman is from the Department of Pediatric Dermatology, Women & Children’s Hospital of Buffalo, New York.

The authors report no conflict of interest.

Correspondence: Canting Guo, MD, Rhode Island Hospital, Jane Brown Building, 593 Eddy St, Providence, RI 02903 ([email protected]).
 

Author and Disclosure Information

Dr. Guo is from the Department of Internal Medicine, Brown University, Providence, Rhode Island. Dr. Sato is from Sato Dermatology, Honolulu, Hawaii. Dr. Rothman is from the Department of Pediatric Dermatology, Women & Children’s Hospital of Buffalo, New York.

The authors report no conflict of interest.

Correspondence: Canting Guo, MD, Rhode Island Hospital, Jane Brown Building, 593 Eddy St, Providence, RI 02903 ([email protected]).
 

Article PDF
Article PDF

The Diagnosis: Allergic Contact Dermatitis to 
Para-phenylenediamine

To darken the color of henna and increase penetrance and staining, para-phenylenediamine (PPD) is added.1 Allergic contact dermatitis is the most common type of hypersensitivity to PPD.2 A retrospective study that examined severe adverse events from applying henna dyes in children found that angioedema of mucosal tissues was the most common severe adverse event; others included renal failure and shock.3

Black henna is associated with multiple cultural practices. For example, Indian weddings contain a henna decoration ceremony for the bride based on the belief that the longer the henna lasts, the longer the marriage lasts. Black henna is favored for this practice, as it lasts longer than red henna.

 

Red henna tattoo on the palmar surfaces of the hands.

Henna (Lawsonia inermis) is a plant that contains the molecule lawsone (naphthoquinone). Lawsone has an intense affinity for keratin; as a result, lawsone is frequently added to temporary body tattoos and hair dyes to create a relatively permanent change in skin or hair color.4 Henna is mixed with hennotannic acid to release the lawsone from the plant. Lawsone and hennotannic acid rarely cause allergic reactions.1,5-7 Once applied to skin, henna takes a few hours to dry, and the resulting color is orange to red.8 Often, PPD is added to henna paste to create a black color, to speed up the drying process, and to increase its longevity.

Para-phenylenediamine has been repeatedly reported to cause allergic contact dermatitis. We describe a case of allergic contact dermatitis secondary to PPD in black henna. Our patient is a clear example that PPD is the allergen in black henna given that there was no reaction to the natural red henna tattoo that was applied at the same time to the palmar surfaces of the hands (Figure). Aside from the bullous reaction to black henna dye described here, other reported presentations include erythema multiforme–like and exudative erythema reactions.9,10

Contact dermatitis lesions from black henna dye can be treated with topical corticosteroids. Patients may develop residual postinflammatory hyperpigmentation or hypopigmentation, leukoderma, keloids, or scars.1,11,12

The Diagnosis: Allergic Contact Dermatitis to 
Para-phenylenediamine

To darken the color of henna and increase penetrance and staining, para-phenylenediamine (PPD) is added.1 Allergic contact dermatitis is the most common type of hypersensitivity to PPD.2 A retrospective study that examined severe adverse events from applying henna dyes in children found that angioedema of mucosal tissues was the most common severe adverse event; others included renal failure and shock.3

Black henna is associated with multiple cultural practices. For example, Indian weddings contain a henna decoration ceremony for the bride based on the belief that the longer the henna lasts, the longer the marriage lasts. Black henna is favored for this practice, as it lasts longer than red henna.

 

Red henna tattoo on the palmar surfaces of the hands.

Henna (Lawsonia inermis) is a plant that contains the molecule lawsone (naphthoquinone). Lawsone has an intense affinity for keratin; as a result, lawsone is frequently added to temporary body tattoos and hair dyes to create a relatively permanent change in skin or hair color.4 Henna is mixed with hennotannic acid to release the lawsone from the plant. Lawsone and hennotannic acid rarely cause allergic reactions.1,5-7 Once applied to skin, henna takes a few hours to dry, and the resulting color is orange to red.8 Often, PPD is added to henna paste to create a black color, to speed up the drying process, and to increase its longevity.

Para-phenylenediamine has been repeatedly reported to cause allergic contact dermatitis. We describe a case of allergic contact dermatitis secondary to PPD in black henna. Our patient is a clear example that PPD is the allergen in black henna given that there was no reaction to the natural red henna tattoo that was applied at the same time to the palmar surfaces of the hands (Figure). Aside from the bullous reaction to black henna dye described here, other reported presentations include erythema multiforme–like and exudative erythema reactions.9,10

Contact dermatitis lesions from black henna dye can be treated with topical corticosteroids. Patients may develop residual postinflammatory hyperpigmentation or hypopigmentation, leukoderma, keloids, or scars.1,11,12

References
  1. Onder M, Atahan CA, Oztas P, et al. Temporary henna tattoo reactions in children. Int J Dermatol. 2001;40:577-579.
  2. Marcoux D, Couture-Trudel PM, Rboulet-Delmas G, 
et al. Sensitization to paraphenylenediame from a streetside temporary tattoo. Pediatr Dermatol. 2002;19:498-502.
  3. Hashim S, Hamza Y, Yahia B, et al. Poisoning from henna dye and para-phenylenediamine mixtures in children in Khartoum. Ann Trop Paediatr. 1992;12:3-6.
  4. Hijji Y, Barare B, Zhang Y. Lawsone (2- hydroxy-1, 
4-naphthoquinone) as a sensitive cyanide and acetate sensor. Sensors and Actuators B: Chemical. 2012;169:106-112.
  5. Neri I, Guareschi E, Savoia F, et al. Childhood allergic contact dermatitis from henna tattoo. Pediatr Dermatol. 2002;19:503-505.
  6. Evans CC, Fleming JD. Allergic contact dermatitis from a henna tattoo. N Engl J Med. 2008;359:627.
  7. Belhadjali H, Akkari H, Youssef M, et al. Bullous allergic contact dermatitis to pure henna in a 3-year-old girl. 
Pediatr Dermatol. 2011;28:580-581.
  8. Najem N, Bagher Zadeh V. Allergic contact dermatitis to black henna. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20:87-88.
  9. Sidwell RU, Francis ND, Basarab T, et al. Vesicular erythema multiforme-like reaction to para-phenylenediamine in a henna tattoo. Pediatr Dermatol. 2008;25:201-204.
  10. Jovanovic DL, Slavkovic-Jovanovic MR. Allergic contact dermatitis from temporary henna tattoo. J Dermatol. 2009;36:63-65.
  11. Valsecchi R, Leghissa P, Di Landro A, et al. 
Persistent leukoderma after henna tattoo. Contact 
Dermatitis. 2007;56:108-109.
  12. Gunasti S, Aksungur VL. Severe inflammatory and keloidal, allergic reaction due to para-phenylenediamine in temporary tattoos. Indian J Dermatol Venereol Leprol. 2010;76:165-167.
References
  1. Onder M, Atahan CA, Oztas P, et al. Temporary henna tattoo reactions in children. Int J Dermatol. 2001;40:577-579.
  2. Marcoux D, Couture-Trudel PM, Rboulet-Delmas G, 
et al. Sensitization to paraphenylenediame from a streetside temporary tattoo. Pediatr Dermatol. 2002;19:498-502.
  3. Hashim S, Hamza Y, Yahia B, et al. Poisoning from henna dye and para-phenylenediamine mixtures in children in Khartoum. Ann Trop Paediatr. 1992;12:3-6.
  4. Hijji Y, Barare B, Zhang Y. Lawsone (2- hydroxy-1, 
4-naphthoquinone) as a sensitive cyanide and acetate sensor. Sensors and Actuators B: Chemical. 2012;169:106-112.
  5. Neri I, Guareschi E, Savoia F, et al. Childhood allergic contact dermatitis from henna tattoo. Pediatr Dermatol. 2002;19:503-505.
  6. Evans CC, Fleming JD. Allergic contact dermatitis from a henna tattoo. N Engl J Med. 2008;359:627.
  7. Belhadjali H, Akkari H, Youssef M, et al. Bullous allergic contact dermatitis to pure henna in a 3-year-old girl. 
Pediatr Dermatol. 2011;28:580-581.
  8. Najem N, Bagher Zadeh V. Allergic contact dermatitis to black henna. Acta Dermatovenerol Alp Pannonica Adriat. 2011;20:87-88.
  9. Sidwell RU, Francis ND, Basarab T, et al. Vesicular erythema multiforme-like reaction to para-phenylenediamine in a henna tattoo. Pediatr Dermatol. 2008;25:201-204.
  10. Jovanovic DL, Slavkovic-Jovanovic MR. Allergic contact dermatitis from temporary henna tattoo. J Dermatol. 2009;36:63-65.
  11. Valsecchi R, Leghissa P, Di Landro A, et al. 
Persistent leukoderma after henna tattoo. Contact 
Dermatitis. 2007;56:108-109.
  12. Gunasti S, Aksungur VL. Severe inflammatory and keloidal, allergic reaction due to para-phenylenediamine in temporary tattoos. Indian J Dermatol Venereol Leprol. 2010;76:165-167.
Issue
Cutis - 96(3)
Issue
Cutis - 96(3)
Page Number
E5-E6
Page Number
E5-E6
Publications
Publications
Topics
Article Type
Display Headline
Painful Skin Lesions on the Hands Following Black Henna Application
Display Headline
Painful Skin Lesions on the Hands Following Black Henna Application
Legacy Keywords
black henna, para-phenylenediamine, allergic contact dermatitis
Legacy Keywords
black henna, para-phenylenediamine, allergic contact dermatitis
Sections
Questionnaire Body

Red henna tattoo on the palmar surfaces of the hands.

A 14-year-old adolescent girl presented with painful skin lesions on the dorsal aspect of the hands of 10 days’ duration. She reported having received red henna tattoo on the palmar surface of the hands and black henna tattoo on the dorsal surface of the hands 1 day prior to development of the lesions. Within 1 day of receiving the tattoo, she developed pruritus, blisters, and pain on the dorsal aspect of the hands. The palms were unaffected. Physical examination revealed erythematous, brown to black bullae and crusts that followed the contours of the henna design on the dorsal aspect of the hands. There were orange and brown henna designs on the patient’s palms, but no erythema, bullae, or induration was noted.

Disallow All Ads
Alternative CME
Article PDF Media